PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34016170-0 2021 Role of CD44 in increasing the potency of mesenchymal stem cell extracellular vesicles by hyaluronic acid in severe pneumonia. Hyaluronic Acid 90-105 CD44 antigen Mus musculus 8-12 33422513-3 2021 Hyaluronic acid (HYA) is a targeting ligand for CD44 receptors overexpressed on inflamed macrophages. Hyaluronic Acid 0-15 CD44 antigen Mus musculus 48-52 33862284-5 2021 The encapsulation of hyaluronic acid (HA) endow the nanohybrids with mammary carcinoma targeting ability and better biocompatibility, owning to CD44+ receptor overexpressed in some cancer cells. Hyaluronic Acid 21-36 CD44 antigen Mus musculus 144-148 33862284-5 2021 The encapsulation of hyaluronic acid (HA) endow the nanohybrids with mammary carcinoma targeting ability and better biocompatibility, owning to CD44+ receptor overexpressed in some cancer cells. Hyaluronic Acid 38-40 CD44 antigen Mus musculus 144-148 33891595-1 2021 CD44 is a transmembrane glycoprotein that binds to hyaluronic acid, plays roles in a number of cellular processes and is expressed in a variety of cell types. Hyaluronic Acid 51-66 CD44 antigen Mus musculus 0-4 33687996-4 2021 Here, we show that hyaluronan is anchored and spatially organized into a 400-500 nm dense glycocalyx by the leukocyte receptor CD44. Hyaluronic Acid 19-29 CD44 antigen Mus musculus 127-131 33412224-0 2021 Hyaluronic acid engrafted metformin loaded graphene oxide nanoparticle as CD44 targeted anti-cancer therapy for triple negative breast cancer. Hyaluronic Acid 0-15 CD44 antigen Mus musculus 74-78 33422513-3 2021 Hyaluronic acid (HYA) is a targeting ligand for CD44 receptors overexpressed on inflamed macrophages. Hyaluronic Acid 17-20 CD44 antigen Mus musculus 48-52 33140225-5 2020 Hyaluronic acid (HA) is a targeting ligand for CD44 receptors overexpressed on activated macrophages. Hyaluronic Acid 0-15 CD44 antigen Mus musculus 47-51 33287831-4 2020 HA coating endows the micelle system the ability of targeting CD44-positive inflammatory macrophages. Hyaluronic Acid 0-2 CD44 antigen Mus musculus 62-66 33140225-5 2020 Hyaluronic acid (HA) is a targeting ligand for CD44 receptors overexpressed on activated macrophages. Hyaluronic Acid 17-19 CD44 antigen Mus musculus 47-51 32982750-0 2020 Development of a Hyaluronic Acid-Based Nanocarrier Incorporating Doxorubicin and Cisplatin as a pH-Sensitive and CD44-Targeted Anti-Breast Cancer Drug Delivery System. Hyaluronic Acid 17-32 CD44 antigen Mus musculus 113-117 32769144-6 2020 RESULTS: Synthesis of hyaluronan-coated chitosan nanoparticles containing plasmid DNA expressing either BMP7 or NGF/NKI resulted in consistently sized nanoparticles, which-following endocytosis driven by CD44+ cells-promoted cellular growth and inhibited fibrotic gene expression in vitro. Hyaluronic Acid 22-32 CD44 antigen Mus musculus 204-208 32816856-4 2020 Because CD44 is a molecular mediator in the TME, we propose here that TAM-influenced CD44 signaling could mediate stemness via the PI3K-4EBP1-SOX2 pathway, possibly by modulating availability of hyaluronic acid (HA), the main CD44 ligand. Hyaluronic Acid 195-210 CD44 antigen Mus musculus 8-12 32816856-4 2020 Because CD44 is a molecular mediator in the TME, we propose here that TAM-influenced CD44 signaling could mediate stemness via the PI3K-4EBP1-SOX2 pathway, possibly by modulating availability of hyaluronic acid (HA), the main CD44 ligand. Hyaluronic Acid 195-210 CD44 antigen Mus musculus 85-89 32816856-4 2020 Because CD44 is a molecular mediator in the TME, we propose here that TAM-influenced CD44 signaling could mediate stemness via the PI3K-4EBP1-SOX2 pathway, possibly by modulating availability of hyaluronic acid (HA), the main CD44 ligand. Hyaluronic Acid 195-210 CD44 antigen Mus musculus 85-89 32982750-2 2020 The cell-surface transmembrane glycoprotein CD44 binds to the extracellular domain of hyaluronic acid (HA), and is overexpressed in breast, ovarian, lung, and stomach cancer. Hyaluronic Acid 86-101 CD44 antigen Mus musculus 44-48 32982750-2 2020 The cell-surface transmembrane glycoprotein CD44 binds to the extracellular domain of hyaluronic acid (HA), and is overexpressed in breast, ovarian, lung, and stomach cancer. Hyaluronic Acid 103-105 CD44 antigen Mus musculus 44-48 32832636-4 2020 The nanocomplex is modified with hyaluronic acid to target CD44 on TNBC cells. Hyaluronic Acid 33-48 CD44 antigen Mus musculus 59-63 32555923-2 2020 Here, the optimal surface charge (-28 mV) and particle size (51 nm) enabled the acid-labile hyaluronic acid pullulan prodrug (HPP)-doxorubicin (Dox)/lapatinib (Lap) conjugate to circulate in the blood for a lengthy period of time and enhance the electron paramagnetic resonance effect, while the targeted molecule hyaluronic acid accelerated CD44 receptor-mediated 4T1 cell internalization. Hyaluronic Acid 92-107 CD44 antigen Mus musculus 342-346 32080830-2 2020 The therapeutic potential of CD44 has been validated by the clinical successes of several CD44 inhibitors, including antibodies and hyaluronan-related drugs. Hyaluronic Acid 132-142 CD44 antigen Mus musculus 29-33 32538139-1 2020 Hyaluronic acid (HA), a glycosaminoglycan in the extracellular matrix, binds to CD44 and Toll-like receptor 4 (TLR4). Hyaluronic Acid 0-15 CD44 antigen Mus musculus 80-84 32538139-1 2020 Hyaluronic acid (HA), a glycosaminoglycan in the extracellular matrix, binds to CD44 and Toll-like receptor 4 (TLR4). Hyaluronic Acid 17-19 CD44 antigen Mus musculus 80-84 32080830-2 2020 The therapeutic potential of CD44 has been validated by the clinical successes of several CD44 inhibitors, including antibodies and hyaluronan-related drugs. Hyaluronic Acid 132-142 CD44 antigen Mus musculus 90-94 31826506-3 2020 The HA-NO-LF nanomicelles could enter host cells via a CD44 mediated endocytosis and release drug gradually upon exposure to endogenous NO. Hyaluronic Acid 4-6 CD44 antigen Mus musculus 55-59 32243129-6 2020 Hyaluronic acid increased the liposomal stability and association to CD44 on ADSC surface. Hyaluronic Acid 0-15 CD44 antigen Mus musculus 69-73 32090232-1 2020 Due to the critical role of CD44 in mediating cell adhesion and migration, CD44-targeted drug delivery via hyaluronan has been extensively explored. Hyaluronic Acid 107-117 CD44 antigen Mus musculus 75-79 32241446-0 2020 Self-assembled hyaluronic acid nanoparticle suppresses fat accumulation via CD44 in diet-induced obese mice. Hyaluronic Acid 15-30 CD44 antigen Mus musculus 76-80 32328438-3 2020 Here, HDAPPS were functionalized with hyaluronic acid (HA) to improve their binding specificity to CT26 mouse CRC cells using HA to target the cancer stem cell marker CD44. Hyaluronic Acid 38-53 CD44 antigen Mus musculus 167-171 31952595-0 2020 Novel dual ROS-sensitive and CD44 receptor targeting nanomicelles based on oligomeric hyaluronic acid for the efficient therapy of atherosclerosis. Hyaluronic Acid 86-101 CD44 antigen Mus musculus 29-33 31200145-5 2019 In this system, nanoparticles modified with hyaluronic acid (HA) showed high-affinity to CD44/CD168 overexpressed-CRC cells, and efficiently targeted to tumor site in a metastatic orthotropic colon cancer mouse model by oral administration. Hyaluronic Acid 44-59 CD44 antigen Mus musculus 89-93 32122838-1 2020 This study aimed to develop hyaluronic acid (HA)-coated nanostructured lipid carriers (NLC) loaded simultaneously with oleanolic acid (OA), ursolic acid (UA) and Ginsenoside Rg3 (Rg3), prepared by electrostatic attraction for delivering OA, UA and Rg3 (OUR), termed HA-OUR-NLC, to tumors over expressing cluster determinant 44(CD44). Hyaluronic Acid 28-43 CD44 antigen Mus musculus 327-331 33405671-6 2019 This study further introduced cell specificity to these liposomal systems using hyaluronic acid-based pH-sensitive polymers, which are recognized by CD44 expressing on antigen presenting cells. Hyaluronic Acid 80-95 CD44 antigen Mus musculus 149-153 33405671-7 2019 pH-Sensitive hyaluronic acid derivative-modified liposomes showed much higher cellular association to antigen presenting cells than to fibroblasts with less CD44 expression. Hyaluronic Acid 13-28 CD44 antigen Mus musculus 157-161 31394112-0 2019 CD44 Receptor-Specific and Redox-Sensitive Nanophotosensitizers of Hyaluronic Acid-Chlorin e6 Tetramer Having Diselenide Linkages for Photodynamic Treatment of Cancer Cells. Hyaluronic Acid 67-82 CD44 antigen Mus musculus 0-4 31200145-5 2019 In this system, nanoparticles modified with hyaluronic acid (HA) showed high-affinity to CD44/CD168 overexpressed-CRC cells, and efficiently targeted to tumor site in a metastatic orthotropic colon cancer mouse model by oral administration. Hyaluronic Acid 61-63 CD44 antigen Mus musculus 89-93 30501644-3 2018 RESULTS: In this study, we developed a kind of targeting nanoparticle system based on cationic albumin functionalized with hyaluronic acid (HA) to target the CD44 overexpressed CSCs. Hyaluronic Acid 123-138 CD44 antigen Mus musculus 158-162 31192580-6 2019 Furthermore, a dual targeting system was established with hyaluronic acid and fucoidan, which were used as agents for targeting CD44 on prostate cancer cells and P-selectin in tumor vasculature, respectively. Hyaluronic Acid 58-73 CD44 antigen Mus musculus 128-132 31380195-2 2019 Hyaluronan (HA), as a selective CD44 targeting group, has been widely used in TDDSs for chemotherapy. Hyaluronic Acid 0-10 CD44 antigen Mus musculus 32-36 31380195-2 2019 Hyaluronan (HA), as a selective CD44 targeting group, has been widely used in TDDSs for chemotherapy. Hyaluronic Acid 12-14 CD44 antigen Mus musculus 32-36 30699364-3 2019 Here, we report on epidermal growth factor receptor and CD44 dual-targeted hyaluronic acid nanogels (EGFR/CD44-NGs) that afford enhanced targetability and protein therapy for metastatic 4T1 breast cancer in vivo. Hyaluronic Acid 75-90 CD44 antigen Mus musculus 56-60 30699364-3 2019 Here, we report on epidermal growth factor receptor and CD44 dual-targeted hyaluronic acid nanogels (EGFR/CD44-NGs) that afford enhanced targetability and protein therapy for metastatic 4T1 breast cancer in vivo. Hyaluronic Acid 75-90 CD44 antigen Mus musculus 106-110 31085359-5 2019 NPs are electrostatically complexed using anionic hyaluronic acid and cationic chitosan as materials, which could increase the accumulation in injured areas and uptake into CD44-overexpressed cells. Hyaluronic Acid 50-65 CD44 antigen Mus musculus 173-177 29894820-7 2019 Although CD44 has been implicated in an array of inflammatory and fibrotic processes such as leukocyte recruitment, T-cell extravasation, and hyaluronic acid (the principal glycosaminoglycan found in the ECM) metabolism, the role of CD44 in cutaneous wound healing and scarring remains unknown. Hyaluronic Acid 142-157 CD44 antigen Mus musculus 9-13 30501644-3 2018 RESULTS: In this study, we developed a kind of targeting nanoparticle system based on cationic albumin functionalized with hyaluronic acid (HA) to target the CD44 overexpressed CSCs. Hyaluronic Acid 140-142 CD44 antigen Mus musculus 158-162 30297743-2 2018 Hyaluronic acid (HA), a pericellular matrix component, supports BMP7 signalling in murine chondrocytes through its receptor CD44. Hyaluronic Acid 0-15 CD44 antigen Mus musculus 124-128 29890852-3 2018 Herein, we developed PLXDC1 small interfering siRNA (siRNA)-incorporated chitosan nanoparticle (CH-NP/siRNA) coated with hyaluronic acid (HA) to target the CD44 receptor on tumor endothelial cells. Hyaluronic Acid 121-136 CD44 antigen Mus musculus 156-160 29890852-3 2018 Herein, we developed PLXDC1 small interfering siRNA (siRNA)-incorporated chitosan nanoparticle (CH-NP/siRNA) coated with hyaluronic acid (HA) to target the CD44 receptor on tumor endothelial cells. Hyaluronic Acid 138-140 CD44 antigen Mus musculus 156-160 30297743-2 2018 Hyaluronic acid (HA), a pericellular matrix component, supports BMP7 signalling in murine chondrocytes through its receptor CD44. Hyaluronic Acid 17-19 CD44 antigen Mus musculus 124-128 30089233-3 2018 Recently, hyaluronan (HA), a ubiquitously expressed glycosaminoglycan in the ECM, was shown to participate in tissue fibrosis and myofibroblast proliferation through interacting with its ubiquitously expressed cell-surface receptor, CD44. Hyaluronic Acid 10-20 CD44 antigen Mus musculus 233-237 30156827-4 2018 As hyaluronan (HA) is an anionic polysaccharide that is widely used for specific binding to CD44 to improve the cellular uptake efficiency in tumor-targeting therapy, in this study, we modified cationic liposomes (LP) with the negatively charged HA at a mass ratio of 10% to prepare targeted HA-modified cationic liposomes (HALP). Hyaluronic Acid 3-13 CD44 antigen Mus musculus 92-96 30156827-4 2018 As hyaluronan (HA) is an anionic polysaccharide that is widely used for specific binding to CD44 to improve the cellular uptake efficiency in tumor-targeting therapy, in this study, we modified cationic liposomes (LP) with the negatively charged HA at a mass ratio of 10% to prepare targeted HA-modified cationic liposomes (HALP). Hyaluronic Acid 15-17 CD44 antigen Mus musculus 92-96 30089233-3 2018 Recently, hyaluronan (HA), a ubiquitously expressed glycosaminoglycan in the ECM, was shown to participate in tissue fibrosis and myofibroblast proliferation through interacting with its ubiquitously expressed cell-surface receptor, CD44. Hyaluronic Acid 22-24 CD44 antigen Mus musculus 233-237 29858680-0 2018 Hyaluronic acid-modified polyamidoamine dendrimer G5-entrapped gold nanoparticles delivering METase gene inhibits gastric tumor growth via targeting CD44+ gastric cancer cells. Hyaluronic Acid 0-15 CD44 antigen Mus musculus 149-153 29858680-5 2018 With the decorating of Hyaluronic acid (HA), a receptor of CD44, nanoparticles exhibit with good biocompatibility and aqueous solubility. Hyaluronic Acid 23-38 CD44 antigen Mus musculus 59-63 32254339-9 2018 These hyaluronic acid-shelled and disulfide-crosslinked micelles with great simplicity and selectivity are highly promising for treating various CD44-overexpressing cancers. Hyaluronic Acid 6-21 CD44 antigen Mus musculus 145-149 30022822-3 2018 Methods: In this study, HA- and CD-modified poly(D,L-lactide-co-glycolide)-poly(ethylene glycol) (PLGA-PEG) copolymers were synthesized and applied to encapsulate 1,2-Dioleoyl-3-trimethylammonium-propane (DOTAP)/pDNA (D/P) lipoplex as CD44 receptor targeting gene delivery nanoparticles (NPs). Hyaluronic Acid 24-26 CD44 antigen Mus musculus 235-239 29723613-0 2018 CD44 targeting biocompatible and biodegradable hyaluronic acid cross-linked zein nanogels for curcumin delivery to cancer cells: In vitro and in vivo evaluation. Hyaluronic Acid 47-62 CD44 antigen Mus musculus 0-4 29315518-0 2018 Hyaluronan-binding by CD44 reduces the memory potential of activated murine CD8 T cells. Hyaluronic Acid 0-10 CD44 antigen Mus musculus 22-26 29315518-6 2018 The hyaluronan-binding CD44+/+ CD8 effector T cells showed increased pAkt expression, higher glucose uptake, and were more susceptible to cell death during the contraction phase compared to non-binding CD44+/+ and CD44-/- OT-I CD8 T cells, suggesting that CD44 and its engagement with hyaluronan skews CD8 T cells toward a terminal effector differentiation state that reduces their ability to form memory cells. Hyaluronic Acid 4-14 CD44 antigen Mus musculus 23-27 29315518-6 2018 The hyaluronan-binding CD44+/+ CD8 effector T cells showed increased pAkt expression, higher glucose uptake, and were more susceptible to cell death during the contraction phase compared to non-binding CD44+/+ and CD44-/- OT-I CD8 T cells, suggesting that CD44 and its engagement with hyaluronan skews CD8 T cells toward a terminal effector differentiation state that reduces their ability to form memory cells. Hyaluronic Acid 4-14 CD44 antigen Mus musculus 202-206 29315518-6 2018 The hyaluronan-binding CD44+/+ CD8 effector T cells showed increased pAkt expression, higher glucose uptake, and were more susceptible to cell death during the contraction phase compared to non-binding CD44+/+ and CD44-/- OT-I CD8 T cells, suggesting that CD44 and its engagement with hyaluronan skews CD8 T cells toward a terminal effector differentiation state that reduces their ability to form memory cells. Hyaluronic Acid 4-14 CD44 antigen Mus musculus 202-206 29315518-6 2018 The hyaluronan-binding CD44+/+ CD8 effector T cells showed increased pAkt expression, higher glucose uptake, and were more susceptible to cell death during the contraction phase compared to non-binding CD44+/+ and CD44-/- OT-I CD8 T cells, suggesting that CD44 and its engagement with hyaluronan skews CD8 T cells toward a terminal effector differentiation state that reduces their ability to form memory cells. Hyaluronic Acid 4-14 CD44 antigen Mus musculus 202-206 29315518-6 2018 The hyaluronan-binding CD44+/+ CD8 effector T cells showed increased pAkt expression, higher glucose uptake, and were more susceptible to cell death during the contraction phase compared to non-binding CD44+/+ and CD44-/- OT-I CD8 T cells, suggesting that CD44 and its engagement with hyaluronan skews CD8 T cells toward a terminal effector differentiation state that reduces their ability to form memory cells. Hyaluronic Acid 285-295 CD44 antigen Mus musculus 23-27 29684048-2 2018 However, this interaction is not constitutive in most immune cells at steady state, as the ability of CD44 to engage hyaluronan is highly regulated. Hyaluronic Acid 117-127 CD44 antigen Mus musculus 102-106 29067996-0 2018 The survival of fetal and bone marrow monocyte-derived alveolar macrophages is promoted by CD44 and its interaction with hyaluronan. Hyaluronic Acid 121-131 CD44 antigen Mus musculus 91-95 29067996-2 2018 They express high levels of CD44 and are one of the few macrophage populations that constitutively bind hyaluronan, a ligand for CD44 and component of pericellular and extracellular matrices. Hyaluronic Acid 104-114 CD44 antigen Mus musculus 129-133 29067996-6 2018 CD44-mediated hyaluronan binding was induced by the alveolar environment, and this interaction promoted alveolar macrophage survival both ex vivo and in vivo. Hyaluronic Acid 14-24 CD44 antigen Mus musculus 0-4 29684048-0 2018 CD44-mediated hyaluronan binding marks proliferating hematopoietic progenitor cells and promotes bone marrow engraftment. Hyaluronic Acid 14-24 CD44 antigen Mus musculus 0-4 29684048-1 2018 CD44 is a widely expressed cell adhesion molecule that binds to the extracellular matrix component, hyaluronan. Hyaluronic Acid 100-110 CD44 antigen Mus musculus 0-4 29684048-3 2018 While activated T cells and macrophages gain the ability to bind hyaluronan by CD44, the status in other immune cells is less studied. Hyaluronic Acid 65-75 CD44 antigen Mus musculus 79-83 29474960-8 2018 In mouse models, intravenous injection of hyaluronan-based nanoparticles showed a selective delivery to subcutaneous CD44-overexpressing tumors, despite a significant liver capture. Hyaluronic Acid 42-52 CD44 antigen Mus musculus 117-121 29474960-11 2018 In conclusion, hyaluronan-based nanoparticles provide active targeting partially mediated by CD44, less-toxic drug release and improved antitumor efficiency. Hyaluronic Acid 15-25 CD44 antigen Mus musculus 93-97 27774557-7 2016 Hyaluronic acid could act as a targeting agent to CD44 (HA receptor), which further improved the in vivo target effect and enhanced in vitro cellular uptake. Hyaluronic Acid 0-15 CD44 antigen Mus musculus 50-54 28385630-2 2017 Here we assess the targetability of a hyaluronic acid nanogel towards CD44 overexpressing cells, in vitro and in vivo. Hyaluronic Acid 38-53 CD44 antigen Mus musculus 70-74 27619521-1 2016 CD44 is a cell surface adhesion molecule and its principal ligand is hyaluronic acid (HA), a key component of the brain"s extracellular matrix. Hyaluronic Acid 69-84 CD44 antigen Mus musculus 0-4 27619521-1 2016 CD44 is a cell surface adhesion molecule and its principal ligand is hyaluronic acid (HA), a key component of the brain"s extracellular matrix. Hyaluronic Acid 86-88 CD44 antigen Mus musculus 0-4 29129754-0 2018 CD44 targeting hyaluronic acid coated lapatinib nanocrystals foster the efficacy against triple-negative breast cancer. Hyaluronic Acid 15-30 CD44 antigen Mus musculus 0-4 28835099-0 2017 Glutathione-Sensitive Hyaluronic Acid-Mercaptopurine Prodrug Linked via Carbonyl Vinyl Sulfide: A Robust and CD44-Targeted Nanomedicine for Leukemia. Hyaluronic Acid 22-37 CD44 antigen Mus musculus 109-113 29071179-0 2017 Novel Hyaluronic Acid Conjugates for Dual Nuclear Imaging and Therapy in CD44-Expressing Tumors in Mice In Vivo. Hyaluronic Acid 6-21 CD44 antigen Mus musculus 73-77 29071179-1 2017 Hyaluronic acid, a natural CD44 receptor ligand, has attracted attention in the past years as a macromolecular delivery of anticancer agents to cancer. Hyaluronic Acid 0-15 CD44 antigen Mus musculus 27-31 29071179-3 2017 This work reports the synthesis of a hyaluronic acid (HA) conjugate for nuclear imaging, and in vivo Gem delivery to CD44-expressing solid tumors in mice. Hyaluronic Acid 54-56 CD44 antigen Mus musculus 117-121 27863652-1 2016 We have investigated the impact of hyaluronic acid (HA)-coating on the targeting capacity of siRNA lipoplexes to CD44-overexpressing tumor cells. Hyaluronic Acid 52-54 CD44 antigen Mus musculus 113-117 27424081-2 2016 Hyaluronic acid (HA) is known to specifically bind with a transmembrane glycoprotein CD44, overexpressed in many types of cancerous cells, and can also be served as micelle carriers. Hyaluronic Acid 0-15 CD44 antigen Mus musculus 85-89 27552547-0 2016 Peritoneal Macrophage-Specific TNF-alpha Gene Silencing in LPS-Induced Acute Inflammation Model Using CD44 Targeting Hyaluronic Acid Nanoparticles. Hyaluronic Acid 117-132 CD44 antigen Mus musculus 102-106 27552547-1 2016 The main goal of this study was to evaluate tumor necrosis factor-alpha (TNF-alpha) gene silencing in peritoneal macrophages upon activation with lipopolysaccharide (LPS), using CD44-targeting hyaluronic acid (HA)-based nanoparticles encapsulating TNF-alpha-specific small interfering RNA (siTNF-alpha). Hyaluronic Acid 193-208 CD44 antigen Mus musculus 178-182 27552547-1 2016 The main goal of this study was to evaluate tumor necrosis factor-alpha (TNF-alpha) gene silencing in peritoneal macrophages upon activation with lipopolysaccharide (LPS), using CD44-targeting hyaluronic acid (HA)-based nanoparticles encapsulating TNF-alpha-specific small interfering RNA (siTNF-alpha). Hyaluronic Acid 210-212 CD44 antigen Mus musculus 178-182 27424081-2 2016 Hyaluronic acid (HA) is known to specifically bind with a transmembrane glycoprotein CD44, overexpressed in many types of cancerous cells, and can also be served as micelle carriers. Hyaluronic Acid 17-19 CD44 antigen Mus musculus 85-89 27560126-1 2016 Layer-by-layer (LbL) technique was employed to modify the surface of doxorubicin (Dox)-loaded bovine serum albumin (BSA) nanoparticles using hyaluronic acid (HA) to enable targeted delivery to overexpressed CD44 receptors in metastatic breast cancer cells. Hyaluronic Acid 158-160 CD44 antigen Mus musculus 207-211 26085682-3 2015 In this article, we identify a distinct subpopulation of cells within the GM-CSF bone marrow-derived DC culture based on their ability to bind hyaluronan (HA), a major component of the extracellular matrix and ligand for CD44. Hyaluronic Acid 143-153 CD44 antigen Mus musculus 221-225 27235150-2 2016 In this study, this limitation was overcome by developing a dual-targeting delivery system based on hyaluronan (HA, a major ligand of CD44) and tetraiodothyroacetic acid (tetrac, a specific ligand of alphavbeta3), which was exploited to carry docetaxel (DTX) for the synergistic active targeting to tumors. Hyaluronic Acid 100-110 CD44 antigen Mus musculus 134-138 26901756-0 2016 Hyaluronic acid modified mesoporous carbon nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells. Hyaluronic Acid 0-15 CD44 antigen Mus musculus 87-91 26999446-2 2016 The transmembrane glycoprotein CD44 is involved in cell adhesion and acts as a receptor for hyaluronic acid and osteopontin. Hyaluronic Acid 92-107 CD44 antigen Mus musculus 31-35 26860184-4 2016 Herein, we developed a CD44 targeted photoacoustic (PA) nanophototherapy agent by conjugating Indocyanine Green (ICG) to hyaluronic acid nanoparticles (HANPs) encapsulated with single-walled carbon nanotubes (SWCNTs), resulting in a theranostic nanocomplex of ICG-HANP/SWCNTs (IHANPT). Hyaluronic Acid 121-136 CD44 antigen Mus musculus 23-27 26505972-0 2015 CD44 and TLR4 mediate hyaluronic acid regulation of Lgr5+ stem cell proliferation, crypt fission, and intestinal growth in postnatal and adult mice. Hyaluronic Acid 22-37 CD44 antigen Mus musculus 0-4 26505972-1 2015 Hyaluronic acid, a glycosaminoglycan in the extracellular matrix, binds to CD44 and Toll-like receptor 4 (TLR4). Hyaluronic Acid 0-15 CD44 antigen Mus musculus 75-79 26505972-6 2015 In the current study, we sought to determine whether the effects of hyaluronic acid on growth were mediated by signaling through CD44 or TLR4 by giving exogenous hyaluronic acid or PEP-1 twice a week from 3-8 wk of age to wild-type, CD44(-/-), and TLR4(-/-) mice. Hyaluronic Acid 68-83 CD44 antigen Mus musculus 129-133 26505972-7 2015 These studies demonstrated that signaling through both CD44 and TLR4 were important in mediating the effects of hyaluronic acid on growth in the small intestine and colon. Hyaluronic Acid 112-127 CD44 antigen Mus musculus 55-59 26505972-10 2015 These studies indicate that endogenous hyaluronic acid increases Lgr5(+) stem cell proliferation, crypt fission, and intestinal lengthening and that these effects are dependent on signaling through CD44 and TLR4. Hyaluronic Acid 39-54 CD44 antigen Mus musculus 198-202 26624007-7 2015 We have previously reported and we show here again that CD44 expression and hyaluronic acid (HA, the principal ligand for CD44) accumulation are detected in pancreatic islets of diabetic NOD mice, but not of non-diabetic DBA/1 mice. Hyaluronic Acid 76-91 CD44 antigen Mus musculus 122-126 26624007-7 2015 We have previously reported and we show here again that CD44 expression and hyaluronic acid (HA, the principal ligand for CD44) accumulation are detected in pancreatic islets of diabetic NOD mice, but not of non-diabetic DBA/1 mice. Hyaluronic Acid 93-95 CD44 antigen Mus musculus 122-126 26577684-0 2015 Modulation of Macrophage Functional Polarity towards Anti-Inflammatory Phenotype with Plasmid DNA Delivery in CD44 Targeting Hyaluronic Acid Nanoparticles. Hyaluronic Acid 125-140 CD44 antigen Mus musculus 110-114 25673209-2 2015 Interleukin-1beta (IL-1beta) elicits the expression of inflammatory mediators through a mechanism involving hyaluronan (HA) degradation, thereby contributing to toll-like receptor 4 (TLR-4) and CD44 activation. Hyaluronic Acid 108-118 CD44 antigen Mus musculus 194-198 25673209-2 2015 Interleukin-1beta (IL-1beta) elicits the expression of inflammatory mediators through a mechanism involving hyaluronan (HA) degradation, thereby contributing to toll-like receptor 4 (TLR-4) and CD44 activation. Hyaluronic Acid 120-122 CD44 antigen Mus musculus 194-198 27311558-0 2016 CD44-Targeted Hyaluronic Acid-Coated Redox-Responsive Hyperbranched Poly(amido amine)/Plasmid DNA Ternary Nanoassemblies for Efficient Gene Delivery. Hyaluronic Acid 14-29 CD44 antigen Mus musculus 0-4 27311558-1 2016 Hyaluronic acid (HA), which can specifically bind to CD44 receptor, is a specific ligand for targeting to CD44-overexpressing cancer cells. Hyaluronic Acid 0-15 CD44 antigen Mus musculus 53-57 27311558-1 2016 Hyaluronic acid (HA), which can specifically bind to CD44 receptor, is a specific ligand for targeting to CD44-overexpressing cancer cells. Hyaluronic Acid 0-15 CD44 antigen Mus musculus 106-110 27311558-1 2016 Hyaluronic acid (HA), which can specifically bind to CD44 receptor, is a specific ligand for targeting to CD44-overexpressing cancer cells. Hyaluronic Acid 17-19 CD44 antigen Mus musculus 53-57 27311558-1 2016 Hyaluronic acid (HA), which can specifically bind to CD44 receptor, is a specific ligand for targeting to CD44-overexpressing cancer cells. Hyaluronic Acid 17-19 CD44 antigen Mus musculus 106-110 26743660-4 2016 ICG was hydrophobically modified prior to loading into hyaluronic acid (HA)-based micelles utilized for CD 44 based-targeting. Hyaluronic Acid 55-70 CD44 antigen Mus musculus 104-109 26743660-4 2016 ICG was hydrophobically modified prior to loading into hyaluronic acid (HA)-based micelles utilized for CD 44 based-targeting. Hyaluronic Acid 72-74 CD44 antigen Mus musculus 104-109 26085682-3 2015 In this article, we identify a distinct subpopulation of cells within the GM-CSF bone marrow-derived DC culture based on their ability to bind hyaluronan (HA), a major component of the extracellular matrix and ligand for CD44. Hyaluronic Acid 155-157 CD44 antigen Mus musculus 221-225 24161254-0 2013 In vivo biodistribution of siRNA and cisplatin administered using CD44-targeted hyaluronic acid nanoparticles. Hyaluronic Acid 80-95 CD44 antigen Mus musculus 66-70 25797678-10 2015 Hyaluronan (HA), a CD44 ligand, was elevated at d1 and d7 post-MI with MMP12i, as a result of decreased fragmentation. Hyaluronic Acid 0-10 CD44 antigen Mus musculus 19-23 25797678-10 2015 Hyaluronan (HA), a CD44 ligand, was elevated at d1 and d7 post-MI with MMP12i, as a result of decreased fragmentation. Hyaluronic Acid 12-14 CD44 antigen Mus musculus 19-23 25592835-1 2015 Hyaluronan (HA), one of the major structural extracellular components in cartilage, regulates cellular responses via receptors such as CD44. Hyaluronic Acid 0-10 CD44 antigen Mus musculus 135-139 25592835-1 2015 Hyaluronan (HA), one of the major structural extracellular components in cartilage, regulates cellular responses via receptors such as CD44. Hyaluronic Acid 12-14 CD44 antigen Mus musculus 135-139 24842660-0 2014 Hyaluronan-based nanocarriers with CD44-overexpressed cancer cell targeting. Hyaluronic Acid 0-10 CD44 antigen Mus musculus 35-39 24842660-1 2014 PURPOSE: The objective of the work was to evaluate the potential of hyaluronan-based nanoparticles as tumor-targeting nano-systems for CD44-overexpressed cancer therapy. Hyaluronic Acid 68-78 CD44 antigen Mus musculus 135-139 25263908-0 2014 Hyaluronic acid-coated solid lipid nanoparticles for targeted delivery of vorinostat to CD44 overexpressing cancer cells. Hyaluronic Acid 0-15 CD44 antigen Mus musculus 88-92 25077968-7 2014 Flow cytometric analysis demonstrated the enrichment of CD44(high)/CD24(low) CSC-like cells in the SP fraction of hyaluronan-overproducing cancer cells. Hyaluronic Acid 114-124 CD44 antigen Mus musculus 56-60 24619562-0 2014 Folate and CD44 receptors dual-targeting hydrophobized hyaluronic acid paclitaxel-loaded polymeric micelles for overcoming multidrug resistance and improving tumor distribution. Hyaluronic Acid 55-70 CD44 antigen Mus musculus 11-15 24157443-0 2014 CD44 mediated hyaluronan adhesion of Toxoplasma gondii-infected leukocytes. Hyaluronic Acid 14-24 CD44 antigen Mus musculus 0-4 24157443-4 2014 In this study, we demonstrate that T. gondii-invaded human and mouse leukocytes express higher level of CD44, a ligand of hyaluronan (HA), and its expression on myeloid and non-myeloid leukocytes causes T. gondii-invaded human and mouse leukocyte to adhere to HA more effectively than non-invaded leukocytes. Hyaluronic Acid 122-132 CD44 antigen Mus musculus 104-108 24161254-3 2013 We recently demonstrated that tandem delivery of siRNAs that downregulate anti-apoptotic genes overexpressed in cisplatin resistant tumors followed by therapeutic challenge using cisplatin loaded CD44 targeted hyaluronic acid (HA) nanoparticle (NP) induced synergistic antitumor response CD44 expressing tumors that are resistant to cisplatin. Hyaluronic Acid 210-225 CD44 antigen Mus musculus 196-200 23615561-1 2013 The natural turnover of free hyaluronic acid (HA) is predominantly based on its CD44-mediated internalisation in leukocytes. Hyaluronic Acid 29-44 CD44 antigen Mus musculus 80-84 24016852-5 2013 Uptake of Dox by CD44-overexpressing KB cells was higher for CHA-rGO than for rGO, and was decreased in the presence of hyaluronic acid through competition for CD44 receptor binding. Hyaluronic Acid 120-135 CD44 antigen Mus musculus 17-21 24016852-5 2013 Uptake of Dox by CD44-overexpressing KB cells was higher for CHA-rGO than for rGO, and was decreased in the presence of hyaluronic acid through competition for CD44 receptor binding. Hyaluronic Acid 120-135 CD44 antigen Mus musculus 160-164 23790635-0 2013 Selective matrix (hyaluronan) interaction with CD44 and RhoGTPase signaling promotes keratinocyte functions and overcomes age-related epidermal dysfunction. Hyaluronic Acid 18-28 CD44 antigen Mus musculus 47-51 24078641-2 2013 It was previously demonstrated that during IRI, hyaluronan (HA) accumulates in the cortical and external medullary interstitium along with an increased expression of its main receptor, CD44, on inflammatory and tubular cells. Hyaluronic Acid 48-58 CD44 antigen Mus musculus 185-189 22776563-1 2013 The aim of our study was to develop hyaluronic acid-coated, paclitaxel-loaded, nanostructured lipid carriers (HA-NLCs) prepared via electrostatic attraction for delivering paclitaxel (PTX) to tumors overexpressing CD44. Hyaluronic Acid 36-51 CD44 antigen Mus musculus 214-218 23633482-0 2013 Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production. Hyaluronic Acid 107-117 CD44 antigen Mus musculus 29-33 23633482-1 2013 CD44, an adhesion molecule that binds to the extracellular matrix, primarily to hyaluronan (HA), has been implicated in cancer cell migration, invasion, and metastasis. Hyaluronic Acid 80-90 CD44 antigen Mus musculus 0-4 23633482-1 2013 CD44, an adhesion molecule that binds to the extracellular matrix, primarily to hyaluronan (HA), has been implicated in cancer cell migration, invasion, and metastasis. Hyaluronic Acid 92-94 CD44 antigen Mus musculus 0-4 23615561-1 2013 The natural turnover of free hyaluronic acid (HA) is predominantly based on its CD44-mediated internalisation in leukocytes. Hyaluronic Acid 46-48 CD44 antigen Mus musculus 80-84 22422467-16 2012 Rolling of hMSCs is regulated by CD29/VCAM-1, whereas CD29/CD44 interactions with VCAM-1, fibronectin, and hyaluronan on HSECs determine firm adhesion both in vitro and in vivo as demonstrated using a murine model of liver injury. Hyaluronic Acid 107-117 CD44 antigen Mus musculus 59-63 23762326-8 2013 CD45(+)CD44(+) cells bound to hyaluronic acid (HA) in diet fed B6 mice but not Cd44(-/-) or Ccr2(-/-) mice. Hyaluronic Acid 30-45 CD44 antigen Mus musculus 7-11 23762326-8 2013 CD45(+)CD44(+) cells bound to hyaluronic acid (HA) in diet fed B6 mice but not Cd44(-/-) or Ccr2(-/-) mice. Hyaluronic Acid 47-49 CD44 antigen Mus musculus 7-11 23547049-5 2013 Engagement of CD44 by its natural ligands, hyaluronic acid or chondroitin sulfate, protected CLL cells from apoptosis, while anti-CD44 small interfering RNAs impaired tumor cell viability. Hyaluronic Acid 43-58 CD44 antigen Mus musculus 14-18 22865853-0 2012 Hyaluronan anchored to activated CD44 on central nervous system vascular endothelial cells promotes lymphocyte extravasation in experimental autoimmune encephalomyelitis. Hyaluronic Acid 0-10 CD44 antigen Mus musculus 33-37 22693353-0 2012 Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma. Hyaluronic Acid 37-52 CD44 antigen Mus musculus 23-27 22894384-3 2012 In this study, we have carried out atomistic molecular dynamics simulations of a protein-carbohydrate complex formed between the hyaluronan binding domain of the murine Cd44 protein and the octasaccharide hyaluronan in explicit water. Hyaluronic Acid 129-139 CD44 antigen Mus musculus 169-173 22894384-3 2012 In this study, we have carried out atomistic molecular dynamics simulations of a protein-carbohydrate complex formed between the hyaluronan binding domain of the murine Cd44 protein and the octasaccharide hyaluronan in explicit water. Hyaluronic Acid 205-215 CD44 antigen Mus musculus 169-173 22721434-0 2012 Hyaluronan injection in murine osteoarthritis prevents TGFbeta 1-induced synovial neovascularization and fibrosis and maintains articular cartilage integrity by a CD44-dependent mechanism. Hyaluronic Acid 0-10 CD44 antigen Mus musculus 163-167 22796382-3 2012 Hyaluronan (HA) fragments act to prime inflammation via CD44 and the toll-like receptor 4 (TLR-4). Hyaluronic Acid 0-10 CD44 antigen Mus musculus 56-60 22460826-4 2012 We carried out atomistic molecular dynamics (MD) simulations of an aqueous solution of the protein-carbohydrate complex formed between the hyaluronan binding domain (HABD) of the murine Cd44 protein and the octasaccharide hyaluronan (HA(8)). Hyaluronic Acid 139-149 CD44 antigen Mus musculus 186-190 22234777-1 2012 Hyaluronan (HA) degradation produces small oligosaccharides that are able to increase pro-inflammatory cytokines in rheumatoid arthritis synovial fibroblasts (RASF) by activating both CD44 and the toll-like receptor 4 (TLR-4). Hyaluronic Acid 0-10 CD44 antigen Mus musculus 184-188 22234777-1 2012 Hyaluronan (HA) degradation produces small oligosaccharides that are able to increase pro-inflammatory cytokines in rheumatoid arthritis synovial fibroblasts (RASF) by activating both CD44 and the toll-like receptor 4 (TLR-4). Hyaluronic Acid 12-14 CD44 antigen Mus musculus 184-188 22460826-4 2012 We carried out atomistic molecular dynamics (MD) simulations of an aqueous solution of the protein-carbohydrate complex formed between the hyaluronan binding domain (HABD) of the murine Cd44 protein and the octasaccharide hyaluronan (HA(8)). Hyaluronic Acid 222-232 CD44 antigen Mus musculus 186-190 22192912-0 2012 Hyaluronan in part mediates IL-1beta-induced inflammation in mouse chondrocytes by up-regulating CD44 receptors. Hyaluronic Acid 0-10 CD44 antigen Mus musculus 97-101 22192912-2 2012 Hyaluronan (HA) depolymerization also contributes to CD44 activation. Hyaluronic Acid 0-10 CD44 antigen Mus musculus 53-57 22192912-2 2012 Hyaluronan (HA) depolymerization also contributes to CD44 activation. Hyaluronic Acid 12-14 CD44 antigen Mus musculus 53-57 22071098-0 2012 The CD44/integrins interplay and the significance of receptor binding and re-presentation in the uptake of RGD-functionalized hyaluronic acid. Hyaluronic Acid 126-141 CD44 antigen Mus musculus 4-8 22197458-1 2012 Hyaluronan (HA) fragments are able to induce inflammation by stimulating both CD44 and toll-like receptor 4 (TLR-4). Hyaluronic Acid 0-10 CD44 antigen Mus musculus 78-82 22197458-1 2012 Hyaluronan (HA) fragments are able to induce inflammation by stimulating both CD44 and toll-like receptor 4 (TLR-4). Hyaluronic Acid 12-14 CD44 antigen Mus musculus 78-82 22071098-2 2012 Hyaluronic acid (HA; three different molecular weights) was functionalized with an RGD-containing peptide; this ancillary ligand allows the macromolecule to bind to alpha(v) integrins in addition to the classical HA internalization receptor (CD44). Hyaluronic Acid 0-15 CD44 antigen Mus musculus 242-246 21885863-8 2011 Importantly, A6 potentiated the CD44-dependent adhesion of cancer cells to hyaluronic acid and activated CD44-mediated signaling, as evidenced by focal adhesion kinase and MAP/ERK kinase phosphorylation. Hyaluronic Acid 75-90 CD44 antigen Mus musculus 32-36 22159602-0 2012 Interactions between CD44 protein and hyaluronan: insights from the computational study. Hyaluronic Acid 38-48 CD44 antigen Mus musculus 21-25 22072421-3 2012 Blocking hyaluronan binding either by CD44 antibodies, CD44-siRNA or hyaluronan decasaccharides (but not hexasaccharides) removed most of the hyaluronan from the surfaces of both human (HaCaT) and mouse keratinocytes, resembling results on cells from CD44-/- animals. Hyaluronic Acid 9-19 CD44 antigen Mus musculus 55-59 21832148-8 2011 The findings indicate that HA and CD44 increase in epidermal keratinocytes in the premalignant hyperplasia induced by UV irradiation and stay elevated in dysplasia and SCC, suggesting that the accumulation of hyaluronan and CD44 is an early marker for malignant transformation and may be a prerequisite for tumor formation. Hyaluronic Acid 209-219 CD44 antigen Mus musculus 34-38 20558727-3 2010 Here, we examined the molecular mechanisms by which NADPH oxidase-generated ROS regulate the expression of CD44 and its principal ligand, hyaluronan (HA), and how CD44-HA interaction affects VSMC proliferation and migration and inflammatory gene expression in apoE(-/-) mice aortas. Hyaluronic Acid 138-148 CD44 antigen Mus musculus 107-111 21471214-4 2011 Mouse bone marrow-derived macrophages stimulated with tumor necrosis factor alpha or lipopolysaccharide and interferon-gamma (LPS/IFNgamma) induced hyaluronan binding by up-regulating CD44 and down-regulating chondroitin sulfation on CD44. Hyaluronic Acid 148-158 CD44 antigen Mus musculus 184-188 21471214-4 2011 Mouse bone marrow-derived macrophages stimulated with tumor necrosis factor alpha or lipopolysaccharide and interferon-gamma (LPS/IFNgamma) induced hyaluronan binding by up-regulating CD44 and down-regulating chondroitin sulfation on CD44. Hyaluronic Acid 148-158 CD44 antigen Mus musculus 234-238 21471214-5 2011 Hyaluronan binding was induced to a lesser extent in interleukin-4 (IL-4)-activated macrophages despite increased CD44 expression, and this was attributable to increased chondroitin sulfation on CD44, as treatment with beta-d-xyloside to prevent chondroitin sulfate addition significantly enhanced hyaluronan binding. Hyaluronic Acid 0-10 CD44 antigen Mus musculus 114-118 21471214-5 2011 Hyaluronan binding was induced to a lesser extent in interleukin-4 (IL-4)-activated macrophages despite increased CD44 expression, and this was attributable to increased chondroitin sulfation on CD44, as treatment with beta-d-xyloside to prevent chondroitin sulfate addition significantly enhanced hyaluronan binding. Hyaluronic Acid 0-10 CD44 antigen Mus musculus 195-199 21471214-7 2011 Thus, inflammatory and anti-inflammatory stimuli differentially regulate the chondroitin sulfation of CD44, which is a dynamic physiological regulator of hyaluronan binding by CD44 in mouse macrophages. Hyaluronic Acid 154-164 CD44 antigen Mus musculus 102-106 21471214-7 2011 Thus, inflammatory and anti-inflammatory stimuli differentially regulate the chondroitin sulfation of CD44, which is a dynamic physiological regulator of hyaluronan binding by CD44 in mouse macrophages. Hyaluronic Acid 154-164 CD44 antigen Mus musculus 176-180 21037098-1 2010 Hyaluronan is a high-molecular mass component of pulmonary extracelluar matrix, and lung injury can generate a low-molecular mass hyaluronan (HA) fragment that functions as endogenous ligand to cell surface receptors CD44 and TLR4. Hyaluronic Acid 0-10 CD44 antigen Mus musculus 217-221 21471214-0 2011 Differential use of chondroitin sulfate to regulate hyaluronan binding by receptor CD44 in Inflammatory and Interleukin 4-activated Macrophages. Hyaluronic Acid 52-62 CD44 antigen Mus musculus 83-87 21360702-1 2011 CD44 is expressed on T cells where its ability to bind hyaluronan is tightly regulated. Hyaluronic Acid 55-65 CD44 antigen Mus musculus 0-4 21360702-5 2011 A small percentage of hyaluronan-binding cells persisted after in vitro activation and had a memory phenotype (CD122(+) CD44(hi)). Hyaluronic Acid 22-32 CD44 antigen Mus musculus 120-124 20463290-9 2011 CD44 can bind and internalize hyaluronic acid (HA), which acts proinflammatory. Hyaluronic Acid 30-45 CD44 antigen Mus musculus 0-4 20463290-9 2011 CD44 can bind and internalize hyaluronic acid (HA), which acts proinflammatory. Hyaluronic Acid 47-49 CD44 antigen Mus musculus 0-4 20857427-0 2011 Fibroblast growth factor-2 stimulates directed migration of periodontal ligament cells via PI3K/AKT signaling and CD44/hyaluronan interaction. Hyaluronic Acid 119-129 CD44 antigen Mus musculus 114-118 20857427-5 2011 Moreover, in response to FGF-2, MPDL22 showed increased CD44 expression, avidity to hyaluronan (HA) partly via CD44, HA production and mRNA expression of HA synthase (Has)-1, 2, and 3. Hyaluronic Acid 84-94 CD44 antigen Mus musculus 56-60 20864681-8 2010 CD44 deficiency was associated with the accumulation of hyaluronan together with reduced gene expression levels of the negative regulators of Toll-like receptor signaling, interleukin-1R-associated kinase M, A20, and suppressor of cytokine signaling 3. Hyaluronic Acid 56-66 CD44 antigen Mus musculus 0-4 19607883-1 2009 BACKGROUND: Hyaluronan (HA) fragments elicit the expression of inflammatory mediators through a mechanism involving the CD44 receptor. Hyaluronic Acid 12-22 CD44 antigen Mus musculus 120-124 20072653-4 2010 This seeding is mediated by integrins as well as by CD44 interaction with hyaluronan (HA). Hyaluronic Acid 74-84 CD44 antigen Mus musculus 52-56 20072653-4 2010 This seeding is mediated by integrins as well as by CD44 interaction with hyaluronan (HA). Hyaluronic Acid 86-88 CD44 antigen Mus musculus 52-56 19781786-0 2009 Engagement of CD44 by hyaluronan suppresses TLR4 signaling and the septic response to LPS. Hyaluronic Acid 22-32 CD44 antigen Mus musculus 14-18 19781786-1 2009 Fragments of hyaluronan released after injury bind and activate TLR4 in a complex with CD44. Hyaluronic Acid 13-23 CD44 antigen Mus musculus 87-91 19781786-2 2009 Here we investigated if the recognition of hyaluronan by CD44 and TLR4 alters lipopolysaccharide (LPS) responsiveness and thus could alter the septic response. Hyaluronic Acid 43-53 CD44 antigen Mus musculus 57-61 19781786-6 2009 Investigation of the mechanism responsible for inhibition of LPS activation showed hyaluronan treatment resulted in an increase in peritoneal macrophage A20 mRNA expression, and that this was significantly reduced in macrophages from Cd44(-/-) mice and Tlr4(-/-) mice. Hyaluronic Acid 83-93 CD44 antigen Mus musculus 234-238 19781786-8 2009 Therefore, our results show that hyaluronan acts through TLR4, CD44 and A20 to stimulate a unique cellular response that can protect against the septic response to LPS. Hyaluronic Acid 33-43 CD44 antigen Mus musculus 63-67 19852812-9 2009 Both osteopontin and hyaluronic acid competitively displaced Biotin-C21 binding to CD44. Hyaluronic Acid 21-36 CD44 antigen Mus musculus 83-87 20429046-2 2010 The reduction of CD44 expression or its ability to properly interact with its key ligand, hyaluronic acid (HA), inhibits migration and subsequent activation of cells within sites of inflammation. Hyaluronic Acid 90-105 CD44 antigen Mus musculus 17-21 20429046-2 2010 The reduction of CD44 expression or its ability to properly interact with its key ligand, hyaluronic acid (HA), inhibits migration and subsequent activation of cells within sites of inflammation. Hyaluronic Acid 107-109 CD44 antigen Mus musculus 17-21 19965872-5 2010 TNF-alpha promoted CD44 expression and moesin phosphorylation by protein kinase C, leading to the pericellular interaction of hyaluronan and CD44. Hyaluronic Acid 126-136 CD44 antigen Mus musculus 19-23 19965872-9 2010 The production of hyaluronan and its interaction with CD44, thus, play an essential role in TNF-alpha-induced EMT and are potential therapeutic targets in fibrotic disorders. Hyaluronic Acid 18-28 CD44 antigen Mus musculus 54-58 19853364-7 2010 Mice lacking the CD44 gene had morphologically normal lenses with a response to lens fiber cell removal similar to wildtype, although they exhibited an increase in cell-associated hyaluronan. Hyaluronic Acid 180-190 CD44 antigen Mus musculus 17-21 19647176-2 2009 Recently, it has been found that hyaluronic acid (HA) shows selective binding to CD44 receptors expressed in most cancer histotypes. Hyaluronic Acid 33-48 CD44 antigen Mus musculus 81-85 19635906-8 2009 Similar salutary effects on FoxP3 expression were observed upon costimulation with hyaluronan, the primary natural ligand for CD44. Hyaluronic Acid 83-93 CD44 antigen Mus musculus 126-130 19647176-2 2009 Recently, it has been found that hyaluronic acid (HA) shows selective binding to CD44 receptors expressed in most cancer histotypes. Hyaluronic Acid 50-52 CD44 antigen Mus musculus 81-85 19601881-1 2009 The cell adhesion molecule CD44 is expressed on the majority of immune cells and is responsible for mediating adhesion to the extracellular matrix glycosaminoglycan, hyaluronan. Hyaluronic Acid 166-176 CD44 antigen Mus musculus 27-31 19601881-3 2009 Under inflammatory conditions, CD44 on endothelial cells presents hyaluronan to CD44 on activated T lymphocytes and mediates a rolling interaction under flow conditions. Hyaluronic Acid 66-76 CD44 antigen Mus musculus 31-35 19601881-3 2009 Under inflammatory conditions, CD44 on endothelial cells presents hyaluronan to CD44 on activated T lymphocytes and mediates a rolling interaction under flow conditions. Hyaluronic Acid 66-76 CD44 antigen Mus musculus 80-84 19601881-2 2009 The binding of CD44 to hyaluronan is induced on T lymphocytes after activation by antigen and on monocytes after stimulation by inflammatory agents. Hyaluronic Acid 23-33 CD44 antigen Mus musculus 15-19 19164299-8 2009 Mice deficient in either CD44 (the major receptor for hyaluronan) or inter-alpha-trypsin inhibitor (molecule that facilitates hyaluronan binding) show similar elevations in hyaluronan but are protected from ozone-induced AHR. Hyaluronic Acid 54-64 CD44 antigen Mus musculus 25-29 19246453-0 2009 Delivery of CD44 shRNA/nanoparticles within cancer cells: perturbation of hyaluronan/CD44v6 interactions and reduction in adenoma growth in Apc Min/+ MICE. Hyaluronic Acid 74-84 CD44 antigen Mus musculus 12-16 19246453-1 2009 Our studies have shown that constitutive interactions between hyaluronan and CD44 on tumor cells induces various anti-apoptotic cell survival pathways through the formation of a multimeric signaling complex that contains activated receptor tyrosine kinases. Hyaluronic Acid 62-72 CD44 antigen Mus musculus 77-81 19246453-2 2009 Inhibition of the hyaluronan-CD44 interactions on tumor cells by hyaluronan-CD44 interaction antagonists suppresses these activities by disassembling the complex. Hyaluronic Acid 18-28 CD44 antigen Mus musculus 29-33 19246453-2 2009 Inhibition of the hyaluronan-CD44 interactions on tumor cells by hyaluronan-CD44 interaction antagonists suppresses these activities by disassembling the complex. Hyaluronic Acid 18-28 CD44 antigen Mus musculus 76-80 19246453-3 2009 Although the anti-tumor activity of hyaluronan-oligosaccharides, a hyaluronan-CD44 interaction antagonist, is effective in sensitizing tumor cells to chemotherapeutic agents and reducing tumor growth in xenografts, hyaluronan-oligosaccharide alone was not effective in reducing tumor progression in Apc Min/+ mice. Hyaluronic Acid 36-46 CD44 antigen Mus musculus 78-82 19164299-11 2009 Intratracheal instillation of endotoxin-free low molecular weight hyaluronan induces AHR dependent on CD44, whereas instillation of high molecular weight hyaluronan protects against ozone-induced AHR. Hyaluronic Acid 66-76 CD44 antigen Mus musculus 102-106 19164299-12 2009 In conclusion, we demonstrate that hyaluronan mediates ozone-induced AHR, which is dependent on the fragment size and both CD44 and inter-alpha-trypsin inhibitor. Hyaluronic Acid 35-45 CD44 antigen Mus musculus 123-127 19164294-6 2009 Treatment of wild type fibroblasts with hyaluronidase and exogenous hyaluronan enhanced ERK1/2 phosphorylation, and treatment with an anti-CD44 antibody that blocks HA-CD44 interaction inhibited the phosphorylation. Hyaluronic Acid 68-78 CD44 antigen Mus musculus 139-143 19164294-6 2009 Treatment of wild type fibroblasts with hyaluronidase and exogenous hyaluronan enhanced ERK1/2 phosphorylation, and treatment with an anti-CD44 antibody that blocks HA-CD44 interaction inhibited the phosphorylation. Hyaluronic Acid 68-78 CD44 antigen Mus musculus 168-172 19164294-7 2009 These results demonstrate that versican is essential for matrix assembly involving hyaluronan and that diminished versican deposition increases free hyaluronan fragments that interact with CD44 and increase phosphorylation of ERK1/2, leading to cellular senescence. Hyaluronic Acid 149-159 CD44 antigen Mus musculus 189-193 18420998-5 2008 Furthermore, CD44 on vascular smooth muscle cells (VSMCs) regulates their hyaluronan (HA)-dependent migration. Hyaluronic Acid 74-84 CD44 antigen Mus musculus 13-17 18579572-6 2008 Indeed, Gal-9 suppressed the binding of hyaluronic acid to CD44 on both B16F10 and Colon26 cells, and also suppressed the binding of vascular cell adhesion molecule-1 to very late antigen-4 on B16F10 cells. Hyaluronic Acid 40-55 CD44 antigen Mus musculus 59-63 18854367-7 2009 Finally, mononuclear cells from CD44-null and toll-like receptor 4 (TLR4) mutant mice were both stimulated with lower molecular weight hyaluronan. Hyaluronic Acid 135-145 CD44 antigen Mus musculus 32-36 18854367-11 2009 An anti-CD44 antibody attenuated the induction of both IL-6 and MCP-1 in lower molecular weight hyaluronan-stimulated PBMC. Hyaluronic Acid 96-106 CD44 antigen Mus musculus 8-12 18854367-12 2009 In both TLR4 mutant and CD44-null mice, the induction of IL-6 by lower molecular weight hyaluronan stimulation was decreased. Hyaluronic Acid 88-98 CD44 antigen Mus musculus 24-28 18768846-2 2008 Small fragment hyaluronan (HA) is released following injury, and is an endogenous ligand for TLR4 as well as CD44. Hyaluronic Acid 15-25 CD44 antigen Mus musculus 109-113 18768846-2 2008 Small fragment hyaluronan (HA) is released following injury, and is an endogenous ligand for TLR4 as well as CD44. Hyaluronic Acid 27-29 CD44 antigen Mus musculus 109-113 18467123-3 2008 We have used the mouse malignant LB lymphoma cell line as a model for comprehensive in vitro and in vivo analyses of the interaction between CD44 and hyaluronic acid (HA), and its relevance to tumor dissemination. Hyaluronic Acid 167-169 CD44 antigen Mus musculus 141-145 18420998-5 2008 Furthermore, CD44 on vascular smooth muscle cells (VSMCs) regulates their hyaluronan (HA)-dependent migration. Hyaluronic Acid 86-88 CD44 antigen Mus musculus 13-17 17702746-9 2007 We observed that both HGF- and high molecular weight hyaluronan (CD44 ligand)-mediated protection from lipopolysaccharide-induced pulmonary vascular hyperpermeability was significantly reduced in CD44 knock-out mice, thus validating these in vitro findings in an in vivo murine model of inflammatory lung injury. Hyaluronic Acid 53-63 CD44 antigen Mus musculus 65-69 17991717-6 2007 In addition, we have identified and validated cortactin as a novel transcriptional target of hyaluronan/CD44s signaling in underpinning breast tumor invasion. Hyaluronic Acid 93-103 CD44 antigen Mus musculus 104-108 17827392-2 2007 CD44, a transmembrane adhesion molecule involved in binding and metabolism of hyaluronan, may have additional functions in regulation of inflammation and phagocytosis. Hyaluronic Acid 78-88 CD44 antigen Mus musculus 0-4 17702746-9 2007 We observed that both HGF- and high molecular weight hyaluronan (CD44 ligand)-mediated protection from lipopolysaccharide-induced pulmonary vascular hyperpermeability was significantly reduced in CD44 knock-out mice, thus validating these in vitro findings in an in vivo murine model of inflammatory lung injury. Hyaluronic Acid 53-63 CD44 antigen Mus musculus 196-200 17885596-1 2007 Perturbations of interaction of hyaluronan (HA) with its receptor CD44 cause multiple errors in axon routing at the mouse optic chiasm. Hyaluronic Acid 32-42 CD44 antigen Mus musculus 66-70 17657222-5 2007 CD44 is a type I transmembrane protein and functions as the major cellular adhesion molecule for hyaluronic acid, a component of the extracellular matrix. Hyaluronic Acid 97-112 CD44 antigen Mus musculus 0-4 17446336-0 2007 Galectin-9 inhibits CD44-hyaluronan interaction and suppresses a murine model of allergic asthma. Hyaluronic Acid 25-35 CD44 antigen Mus musculus 20-24 17507906-4 2007 In vitro, hyaluronic acid promoted a dose-dependent migration of the stem cells that was inhibited by an anti-CD44 blocking monoclonal antibody. Hyaluronic Acid 10-25 CD44 antigen Mus musculus 110-114 17507906-9 2007 Reconstitution by transfection of CD44 knockout stem cells with cDNA encoding wild-type CD44, but not a loss of function CD44 unable to bind hyaluronic acid, restored in vitro migration and in vivo localization of the cells to injured kidneys. Hyaluronic Acid 141-156 CD44 antigen Mus musculus 34-38 17400552-0 2007 Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on Toll-like receptor 4, CD44, and MD-2. Hyaluronic Acid 15-25 CD44 antigen Mus musculus 123-127 17581255-2 2007 In a recent report we have shown that the major CD44 ligand, hyaluronan (HA), is colocalized with CD44 at the midline of the chiasm, suggesting a possible contribution to the control of axon routing in the chiasm. Hyaluronic Acid 61-71 CD44 antigen Mus musculus 98-102 17581255-2 2007 In a recent report we have shown that the major CD44 ligand, hyaluronan (HA), is colocalized with CD44 at the midline of the chiasm, suggesting a possible contribution to the control of axon routing in the chiasm. Hyaluronic Acid 73-75 CD44 antigen Mus musculus 48-52 17581255-2 2007 In a recent report we have shown that the major CD44 ligand, hyaluronan (HA), is colocalized with CD44 at the midline of the chiasm, suggesting a possible contribution to the control of axon routing in the chiasm. Hyaluronic Acid 73-75 CD44 antigen Mus musculus 98-102 17581255-2 2007 In a recent report we have shown that the major CD44 ligand, hyaluronan (HA), is colocalized with CD44 at the midline of the chiasm, suggesting a possible contribution to the control of axon routing in the chiasm. Hyaluronic Acid 61-71 CD44 antigen Mus musculus 48-52 17400552-6 2007 Explanation for the unique response to hyaluronan was provided by observations that a lack of TLR4 or CD44 in mice diminished the response to sterile injury, and together with MD-2, was required for responsiveness to hyaluronan in vitro. Hyaluronic Acid 39-49 CD44 antigen Mus musculus 102-106 17400552-6 2007 Explanation for the unique response to hyaluronan was provided by observations that a lack of TLR4 or CD44 in mice diminished the response to sterile injury, and together with MD-2, was required for responsiveness to hyaluronan in vitro. Hyaluronic Acid 217-227 CD44 antigen Mus musculus 102-106 17400552-7 2007 Thus, a unique complex of TLR4, MD-2, and CD44 recognizes hyaluronan. Hyaluronic Acid 58-68 CD44 antigen Mus musculus 42-46 17277154-1 2007 CD44 is a transmembrane adhesion molecule and hemopoietic CD44 has an essential role in hyaluronan clearance and resolution of noninfectious lung injury. Hyaluronic Acid 88-98 CD44 antigen Mus musculus 0-4 17277154-1 2007 CD44 is a transmembrane adhesion molecule and hemopoietic CD44 has an essential role in hyaluronan clearance and resolution of noninfectious lung injury. Hyaluronic Acid 88-98 CD44 antigen Mus musculus 58-62 17039568-3 2006 Expression of the activated, hyaluronan-binding form of CD44, and of CD49d, was elevated in draining lymph node cells (LNC) of AA-affected mice as compared to control mice. Hyaluronic Acid 29-39 CD44 antigen Mus musculus 56-60 17082640-2 2006 We report that CD44, a hyaluronic acid (HA) binding protein that mediates cell-cell and cell-matrix interactions, facilitates the interaction of E. coli with urothelial cells and thus the infection of the host. Hyaluronic Acid 23-38 CD44 antigen Mus musculus 15-19 17082640-2 2006 We report that CD44, a hyaluronic acid (HA) binding protein that mediates cell-cell and cell-matrix interactions, facilitates the interaction of E. coli with urothelial cells and thus the infection of the host. Hyaluronic Acid 40-42 CD44 antigen Mus musculus 15-19 16785522-5 2006 Stimulation of CD44 through Ab cross-linking or binding to its natural ligands hyaluronan and osteopontin induced NKT cells to secrete cytokines, up-regulate activation markers, undergo morphological changes, and resist activation-induced cell death, whereas conventional T cells only exhibited changes in morphology and protection from activation-induced cell death. Hyaluronic Acid 79-89 CD44 antigen Mus musculus 15-19 16785522-6 2006 This CD44-specific stimulation of NKT cells correlated with their ability to bind hyaluronan. Hyaluronic Acid 82-92 CD44 antigen Mus musculus 5-9 15746573-1 2005 In this review we focus on a promising novel histone deacetylase (HDAC) inhibitor (HA-But) obtained by the esterification of butyric acid (BA), the smallest HDAC inhibitor, with hyaluronic acid (HA), the main constituent of the extracellular matrix which selectively recognizes a transmembrane receptor (CD44) overexpressed in most primary cancers and associated with tumor progression. Hyaluronic Acid 178-193 CD44 antigen Mus musculus 304-308 16452493-10 2006 With the use of these cells, it is shown that interaction between CD44 and its ligand hyaluronic acid enhances the proapoptotic effect of TGF-beta1 but not thrombospondin-1 on endothelial cells, contributing to the degeneration of the capillary network. Hyaluronic Acid 86-101 CD44 antigen Mus musculus 66-70 16455948-1 2006 CD44, a transmembrane adhesion molecule involved in binding and metabolism of hyaluronan, has additional functions in inflammatory and immune responses, contributing to the ingestion and clearance of particles and apoptotic cells. Hyaluronic Acid 78-88 CD44 antigen Mus musculus 0-4 16061657-2 2005 Historically, primary breast tumor epithelium has been investigated in isolation from other tissue components, leading to the common interpretation that CD44 and its primary ligand, hyaluronan, promote invasion. Hyaluronic Acid 182-192 CD44 antigen Mus musculus 153-157 16061657-5 2005 Localization studies, in combination with a novel hyaluronan synthase-GFP transgenic mouse, show a restricted pattern of expression for CD44 and hyaluronan. Hyaluronic Acid 50-60 CD44 antigen Mus musculus 136-140 16061657-7 2005 This distinct CD44 and hyaluronan pattern of distribution suggests a role for epithelial-stromal interaction in CD44 function. Hyaluronic Acid 23-33 CD44 antigen Mus musculus 112-116 16061657-9 2005 Invasion of CD44-positive tumor cells was inhibited in hyaluronan-containing matrices, whereas blocking CD44-hyaluronan association increased invasion. Hyaluronic Acid 55-65 CD44 antigen Mus musculus 12-16 16061657-9 2005 Invasion of CD44-positive tumor cells was inhibited in hyaluronan-containing matrices, whereas blocking CD44-hyaluronan association increased invasion. Hyaluronic Acid 109-119 CD44 antigen Mus musculus 104-108 16061657-10 2005 Collectively, these data show that during breast cancer progression, hyaluronan-CD44 dynamics occurring through epithelial-stromal interactions are protective against metastasis. Hyaluronic Acid 69-79 CD44 antigen Mus musculus 80-84 15854028-6 2005 The hyaluronan response was associated with a strong induction of has2 and has3 mRNA, slightly higher CD44 expression, and considerable epidermal hyperplasia. Hyaluronic Acid 4-14 CD44 antigen Mus musculus 102-106 15746573-1 2005 In this review we focus on a promising novel histone deacetylase (HDAC) inhibitor (HA-But) obtained by the esterification of butyric acid (BA), the smallest HDAC inhibitor, with hyaluronic acid (HA), the main constituent of the extracellular matrix which selectively recognizes a transmembrane receptor (CD44) overexpressed in most primary cancers and associated with tumor progression. Hyaluronic Acid 83-85 CD44 antigen Mus musculus 304-308 15619667-0 2005 Hyaluronan increases RANKL expression in bone marrow stromal cells through CD44. Hyaluronic Acid 0-10 CD44 antigen Mus musculus 75-79 15632176-6 2005 Furthermore, in HCT116 and TA3/St cells, inhibition of endogenous hyaluronan-CD44 interaction causes disassembly of a constitutive, lipid raft-associated, signaling complex containing phosphorylated ErbB2, CD44, ezrin, phosphoinositide 3-kinase, and the chaperone molecules, Hsp90 and cdc37. Hyaluronic Acid 66-76 CD44 antigen Mus musculus 77-81 15632176-6 2005 Furthermore, in HCT116 and TA3/St cells, inhibition of endogenous hyaluronan-CD44 interaction causes disassembly of a constitutive, lipid raft-associated, signaling complex containing phosphorylated ErbB2, CD44, ezrin, phosphoinositide 3-kinase, and the chaperone molecules, Hsp90 and cdc37. Hyaluronic Acid 66-76 CD44 antigen Mus musculus 206-210 15623776-5 2005 The cytotoxicity of sCD44 was verified by heat-inactivation, pretreatment with a pan-caspase inhibitor, and coadministration of anti-CD44 neutralizing antibody or hyaluronic acid (HA). Hyaluronic Acid 163-178 CD44 antigen Mus musculus 21-25 15623776-5 2005 The cytotoxicity of sCD44 was verified by heat-inactivation, pretreatment with a pan-caspase inhibitor, and coadministration of anti-CD44 neutralizing antibody or hyaluronic acid (HA). Hyaluronic Acid 180-182 CD44 antigen Mus musculus 21-25 15596723-2 2004 Furthermore, we show that under the inflammatory cascade, RHAMM (receptor for hyaluronan-mediated motility), a hyaluronan receptor distinct from CD44, compensates for the loss of CD44 in binding hyaluronic acid, supporting cell migration, up-regulating genes involved with inflammation (as assessed by microarrays containing 13,000 cDNA clones), and exacerbating collagen-induced arthritis. Hyaluronic Acid 195-210 CD44 antigen Mus musculus 179-183 15596723-3 2004 Interestingly, we further found that the compensation for loss of the CD44 gene does not occur because of enhanced expression of the redundant gene (RHAMM), but rather because the loss of CD44 allows increased accumulation of the hyaluronic acid substrate, with which both CD44 and RHAMM engage, thus enabling augmented signaling through RHAMM. Hyaluronic Acid 230-245 CD44 antigen Mus musculus 70-74 15596723-3 2004 Interestingly, we further found that the compensation for loss of the CD44 gene does not occur because of enhanced expression of the redundant gene (RHAMM), but rather because the loss of CD44 allows increased accumulation of the hyaluronic acid substrate, with which both CD44 and RHAMM engage, thus enabling augmented signaling through RHAMM. Hyaluronic Acid 230-245 CD44 antigen Mus musculus 188-192 15596723-3 2004 Interestingly, we further found that the compensation for loss of the CD44 gene does not occur because of enhanced expression of the redundant gene (RHAMM), but rather because the loss of CD44 allows increased accumulation of the hyaluronic acid substrate, with which both CD44 and RHAMM engage, thus enabling augmented signaling through RHAMM. Hyaluronic Acid 230-245 CD44 antigen Mus musculus 188-192 15585887-1 2004 Lymphocyte CD44 interactions with hyaluronan localized on the endothelium have been demonstrated to mediate rolling and regulate lymphocyte entry into sites of chronic inflammation. Hyaluronic Acid 34-44 CD44 antigen Mus musculus 11-15 15383611-7 2004 These anti-Id x anti-CD44 bispecific Abs blocked 38C-13 cell adhesion to hyaluronic acid, while not affecting adhesion of Id-negative cells. Hyaluronic Acid 73-88 CD44 antigen Mus musculus 21-25 15472675-9 2004 Immunohistochemistry and Western blot analysis demonstrated that the CD44 protein expression of cancer cells was higher in the sodium hyaluronate group vs. the control group. Hyaluronic Acid 127-145 CD44 antigen Mus musculus 69-73 15472675-10 2004 CONCLUSIONS: In this study, sodium hyaluronate enhanced both tumor growth and CD44 expression of cancer cells at wound sites, suggesting that the use of sodium hyaluronate for EMR might stimulate the growth of residual tumor cells. Hyaluronic Acid 28-46 CD44 antigen Mus musculus 78-82 15472675-10 2004 CONCLUSIONS: In this study, sodium hyaluronate enhanced both tumor growth and CD44 expression of cancer cells at wound sites, suggesting that the use of sodium hyaluronate for EMR might stimulate the growth of residual tumor cells. Hyaluronic Acid 153-171 CD44 antigen Mus musculus 78-82 15361838-0 2004 Recombinant CD44-HABD is a novel and potent direct angiogenesis inhibitor enforcing endothelial cell-specific growth inhibition independently of hyaluronic acid binding. Hyaluronic Acid 145-160 CD44 antigen Mus musculus 12-16 15361838-1 2004 CD44 is the main cellular receptor for hyaluronic acid (HA). Hyaluronic Acid 39-54 CD44 antigen Mus musculus 0-4 15361838-1 2004 CD44 is the main cellular receptor for hyaluronic acid (HA). Hyaluronic Acid 56-58 CD44 antigen Mus musculus 0-4 15325806-8 2004 Cell adhesion to hyaluronate increases in parallel with CD44 expression. Hyaluronic Acid 17-28 CD44 antigen Mus musculus 56-60 15919379-7 2004 Thus, both polarization and directed migration of neutrophils are dependent on the expression of CD44 and its interaction with hyaluronan, which could modulate neutrophil migration into inflamed tissues. Hyaluronic Acid 127-137 CD44 antigen Mus musculus 97-101 15269158-1 2004 PURPOSE: The purpose is to evaluate the CD44-mediated cellular targeting of HA-But, a hyaluronic acid esterified with butyric acid (But) residues, to hepatocellular carcinoma cell lines in vitro and to hepatic tumor metastases in vivo. Hyaluronic Acid 86-101 CD44 antigen Mus musculus 40-44 15136928-7 2004 With hyaluronic acid, the frequency of port-site metastasis and the weight of port-site metastatic tumors were significantly decreased both by anti-integrin and by anti-CD44 antibody (control vs anti-integrin and anti-CD44; 95% and 8.5 +/- 7.2 mg vs 50% and 3.1 +/- 4.3 mg and 55% and 3.3 +/- 5.1 mg, respectively; p < 0.05). Hyaluronic Acid 5-20 CD44 antigen Mus musculus 169-173 15256056-1 2004 Naturally occurring high-Mr hyaluronan, bound to the surface of nanoliposomes (denoted targeted hyaluronan liposomes, or tHA-LIP), is a candidate for active targeting to tumors, many of which overexpress the hyaluronan receptors CD44 and RHAMM. Hyaluronic Acid 28-38 CD44 antigen Mus musculus 229-233 15136928-7 2004 With hyaluronic acid, the frequency of port-site metastasis and the weight of port-site metastatic tumors were significantly decreased both by anti-integrin and by anti-CD44 antibody (control vs anti-integrin and anti-CD44; 95% and 8.5 +/- 7.2 mg vs 50% and 3.1 +/- 4.3 mg and 55% and 3.3 +/- 5.1 mg, respectively; p < 0.05). Hyaluronic Acid 5-20 CD44 antigen Mus musculus 218-222 15158613-1 2004 CD44 on leukocytes binds to its glycosaminoglycan (GAG) ligand, hyaluronic acid, and mediates the rolling of leukocytes on vascular endothelial cells. Hyaluronic Acid 64-79 CD44 antigen Mus musculus 0-4 15153314-3 2004 The studies reported here reveal that resting NK cells constitutively express CD44 that is in an inactive form that does not bind to hyaluronan (HA), the principal known ligand for CD44. Hyaluronic Acid 133-143 CD44 antigen Mus musculus 78-82 15153314-3 2004 The studies reported here reveal that resting NK cells constitutively express CD44 that is in an inactive form that does not bind to hyaluronan (HA), the principal known ligand for CD44. Hyaluronic Acid 145-147 CD44 antigen Mus musculus 78-82 15070674-2 2004 We report that the adhesion receptor CD44 and its major ligand, hyaluronic acid (HA), are essential for homing into the bone marrow (BM) and spleen of nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice and engraftment by human HSCs. Hyaluronic Acid 64-79 CD44 antigen Mus musculus 37-41 15070674-2 2004 We report that the adhesion receptor CD44 and its major ligand, hyaluronic acid (HA), are essential for homing into the bone marrow (BM) and spleen of nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice and engraftment by human HSCs. Hyaluronic Acid 81-83 CD44 antigen Mus musculus 37-41 12819101-10 2003 Interestingly, coincubation of BMM with hyaluronidase or anti-CD44 antibodies that selectively inhibit hyaluronan binding increased intracellular listerial proliferation. Hyaluronic Acid 103-113 CD44 antigen Mus musculus 62-66 12540844-0 2003 Role of the extracellular and cytoplasmic domains of CD44 in the rolling interaction of lymphoid cells with hyaluronan under physiologic flow. Hyaluronic Acid 108-118 CD44 antigen Mus musculus 53-57 12750406-6 2003 Treatment with anti-CD44 mAb inhibited the increased levels of hyaluronic acid (HA) and leukotriene concentrations in BALF that typically result from antigen challenge. Hyaluronic Acid 63-78 CD44 antigen Mus musculus 20-24 12750406-6 2003 Treatment with anti-CD44 mAb inhibited the increased levels of hyaluronic acid (HA) and leukotriene concentrations in BALF that typically result from antigen challenge. Hyaluronic Acid 80-82 CD44 antigen Mus musculus 20-24 12439345-0 2002 Regulation of interleukin-2-induced vascular leak syndrome by targeting CD44 using hyaluronic acid and anti-CD44 antibodies. Hyaluronic Acid 83-98 CD44 antigen Mus musculus 72-76 12488494-3 2002 CD44 and its ligand hyaluronan were up-regulated in the eye during EAU. Hyaluronic Acid 20-30 CD44 antigen Mus musculus 0-4 12511569-0 2003 E-cadherin negatively regulates CD44-hyaluronan interaction and CD44-mediated tumor invasion and branching morphogenesis. Hyaluronic Acid 37-47 CD44 antigen Mus musculus 32-36 12439345-2 2002 In the current study, we tested whether treatment with mAbs against CD44 or hyaluronic acid (HA), the ligand for CD44, can abrogate IL-2-induced VLS. Hyaluronic Acid 76-91 CD44 antigen Mus musculus 113-117 12439345-2 2002 In the current study, we tested whether treatment with mAbs against CD44 or hyaluronic acid (HA), the ligand for CD44, can abrogate IL-2-induced VLS. Hyaluronic Acid 93-95 CD44 antigen Mus musculus 113-117 12207337-1 2002 CD44 has been implicated in hyaluronan (HA)-dependent primary adhesion between leukocytes and endothelium. Hyaluronic Acid 28-38 CD44 antigen Mus musculus 0-4 11935029-3 2002 CD44-deficient mice succumb to unremitting inflammation following noninfectious lung injury, characterized by impaired clearance of apoptotic neutrophils, persistent accumulation of hyaluronan fragments at the site of tissue injury, and impaired activation of transforming growth factor-beta1. Hyaluronic Acid 182-192 CD44 antigen Mus musculus 0-4 11929781-6 2002 A subset of IgG plasma cells also bound hyaluronic acid, the ligand for CD44. Hyaluronic Acid 40-55 CD44 antigen Mus musculus 72-76 12521133-0 2002 Interaction of CD44 with different forms of hyaluronic acid. Hyaluronic Acid 44-59 CD44 antigen Mus musculus 15-19 12521133-2 2002 Interaction between hyaluronic acid (HA) and CD44 has been considered a key event in tumor invasion and metastasis. Hyaluronic Acid 20-35 CD44 antigen Mus musculus 45-49 12521133-2 2002 Interaction between hyaluronic acid (HA) and CD44 has been considered a key event in tumor invasion and metastasis. Hyaluronic Acid 37-39 CD44 antigen Mus musculus 45-49 11696432-5 2001 Intravenous injection of rmTSG-6 induced a dramatic reduction of edema in acutely inflamed joints by immobilizing CD44-bound hyaluronan and, in long-term treatment, protected cartilage from degradation and blocked subchondral and periosteal bone erosion in inflamed joints. Hyaluronic Acid 125-135 CD44 antigen Mus musculus 114-118 12095240-4 2002 The endogenous factor hyaluronic acid (HA), an extracellular matrix component, also promotes cell migration through its receptor CD44. Hyaluronic Acid 22-37 CD44 antigen Mus musculus 129-133 12095240-4 2002 The endogenous factor hyaluronic acid (HA), an extracellular matrix component, also promotes cell migration through its receptor CD44. Hyaluronic Acid 39-41 CD44 antigen Mus musculus 129-133 11581304-10 2001 Finally, we demonstrate that hyaluronan, the principal ligand for CD44, is upregulated in atherosclerotic lesions of apoE-deficient mice and that the low-molecular-weight proinflammatory forms of hyaluronan stimulate VCAM-1 expression and proliferation of cultured primary aortic smooth muscle cells, whereas high-molecular-weight forms of hyaluronan inhibit smooth muscle cell proliferation. Hyaluronic Acid 29-39 CD44 antigen Mus musculus 66-70 11682606-0 2001 CD44-dependent lymphoma cell dissemination: a cell surface CD44 variant, rather than standard CD44, supports in vitro lymphoma cell rolling on hyaluronic acid substrate and its in vivo accumulation in the peripheral lymph nodes. Hyaluronic Acid 143-158 CD44 antigen Mus musculus 0-4 11682606-0 2001 CD44-dependent lymphoma cell dissemination: a cell surface CD44 variant, rather than standard CD44, supports in vitro lymphoma cell rolling on hyaluronic acid substrate and its in vivo accumulation in the peripheral lymph nodes. Hyaluronic Acid 143-158 CD44 antigen Mus musculus 59-63 11682606-0 2001 CD44-dependent lymphoma cell dissemination: a cell surface CD44 variant, rather than standard CD44, supports in vitro lymphoma cell rolling on hyaluronic acid substrate and its in vivo accumulation in the peripheral lymph nodes. Hyaluronic Acid 143-158 CD44 antigen Mus musculus 59-63 11581304-10 2001 Finally, we demonstrate that hyaluronan, the principal ligand for CD44, is upregulated in atherosclerotic lesions of apoE-deficient mice and that the low-molecular-weight proinflammatory forms of hyaluronan stimulate VCAM-1 expression and proliferation of cultured primary aortic smooth muscle cells, whereas high-molecular-weight forms of hyaluronan inhibit smooth muscle cell proliferation. Hyaluronic Acid 196-206 CD44 antigen Mus musculus 66-70 11581304-10 2001 Finally, we demonstrate that hyaluronan, the principal ligand for CD44, is upregulated in atherosclerotic lesions of apoE-deficient mice and that the low-molecular-weight proinflammatory forms of hyaluronan stimulate VCAM-1 expression and proliferation of cultured primary aortic smooth muscle cells, whereas high-molecular-weight forms of hyaluronan inhibit smooth muscle cell proliferation. Hyaluronic Acid 196-206 CD44 antigen Mus musculus 66-70 11526540-2 2001 These cells, expressing the adhesion receptor, CD44, are largely depleted from the liver by a single intravenous injection of low-molecular-weight fragments of hyaluronic acid (LMW-HA). Hyaluronic Acid 160-175 CD44 antigen Mus musculus 47-51 11403716-0 2001 Differentiation stages of eosinophils characterized by hyaluronic acid binding via CD44 and responsiveness to stimuli. Hyaluronic Acid 55-70 CD44 antigen Mus musculus 83-87 11032859-7 2000 These results provide evidence that CD44 serves as a receptor for GAS colonization of the pharynx and support the potential efficacy of disrupting the interaction between the GAS hyaluronic acid capsule and CD44 as a novel approach to preventing pharyngeal infection. Hyaluronic Acid 179-194 CD44 antigen Mus musculus 36-40 11289136-2 2001 CD44 is a receptor that binds to hyaluronan (HA), a carbohydrate consisting of beta1,3 N-acetyl glucosaminyl-beta1,4 glucuronide. Hyaluronic Acid 33-43 CD44 antigen Mus musculus 0-4 11289136-3 2001 We hypothesized that the incorporation of phosphatidylethanolamine lipid derivatives-containing HA oligosaccharides (HA-PE) into liposomes could target drug-containing liposomes to tumor cells that express CD44. Hyaluronic Acid 96-98 CD44 antigen Mus musculus 206-210 10618410-2 2000 Histochemical analysis of diabetic pancreata revealed that mononuclear cells infiltrating the islets and causing autoimmune insulitis, as well as local islet cells, express the CD44 receptor; hyaluronic acid, the principal ligand of CD44, is detected in the islet periphery and islet endothelium. Hyaluronic Acid 192-207 CD44 antigen Mus musculus 177-181 10825241-5 2000 The co-localization of OPN and CD44 was prominent at the leading edge of migrating fibroblasts, where OPN also co-localized with the ezrin/radixin/moesin (ERM) protein ezrin, as well as in cell processes and at attachment sites of hyaluronan-coated beads. Hyaluronic Acid 231-241 CD44 antigen Mus musculus 31-35 10825241-10 2000 These studies indicate that OPN exists as an integral component of a hyaluronan-CD44-ERM attachment complex that is involved in the migration of embryonic fibroblasts, activated macrophages, and metastatic cells. Hyaluronic Acid 69-79 CD44 antigen Mus musculus 80-84 10854236-0 2000 Perturbation of hyaluronan interactions by soluble CD44 inhibits growth of murine mammary carcinoma cells in ascites. Hyaluronic Acid 16-26 CD44 antigen Mus musculus 51-55 10854236-7 2000 Thus, perturbation of hyaluronan interactions by soluble CD44 has a direct effect on the growth characteristics of these tumor cells, leading to inhibition of anchorage-independent growth in vitro and ascites growth in vivo. Hyaluronic Acid 22-32 CD44 antigen Mus musculus 57-61 10772817-3 2000 This spread morphology is different from that of these same cells when adhering to immobilized hyaluronan, the natural ligand of CD44. Hyaluronic Acid 95-105 CD44 antigen Mus musculus 129-133 10772817-7 2000 Transfection of CD44-negative lymphoid cells with full-length and tailless CD44 enabled these cells to bind to both immobilized hyaluronan and mAb. Hyaluronic Acid 128-138 CD44 antigen Mus musculus 16-20 10772817-7 2000 Transfection of CD44-negative lymphoid cells with full-length and tailless CD44 enabled these cells to bind to both immobilized hyaluronan and mAb. Hyaluronic Acid 128-138 CD44 antigen Mus musculus 75-79 10772817-9 2000 Our results suggest that CD44 may mediate lymphocyte attachment to its carbohydrate ligand hyaluronan by mechanisms broadly similar to those used by selectins. Hyaluronic Acid 91-101 CD44 antigen Mus musculus 25-29 10712440-3 2000 We recently showed that binding of CD44 on activated T lymphocytes to endothelial hyaluronan (HA) mediates a primary adhesive interaction under shear stress, permitting extravasation at sites of inflammation. Hyaluronic Acid 82-92 CD44 antigen Mus musculus 35-39 10712440-3 2000 We recently showed that binding of CD44 on activated T lymphocytes to endothelial hyaluronan (HA) mediates a primary adhesive interaction under shear stress, permitting extravasation at sites of inflammation. Hyaluronic Acid 94-96 CD44 antigen Mus musculus 35-39 10618410-2 2000 Histochemical analysis of diabetic pancreata revealed that mononuclear cells infiltrating the islets and causing autoimmune insulitis, as well as local islet cells, express the CD44 receptor; hyaluronic acid, the principal ligand of CD44, is detected in the islet periphery and islet endothelium. Hyaluronic Acid 192-207 CD44 antigen Mus musculus 233-237 10618410-6 2000 Administration of the enzyme hyaluronidase also induced appreciable resistance to insulin-dependent diabetes mellitus, suggesting that the CD44-hyaluronic acid interaction is involved in the development of the disease. Hyaluronic Acid 144-159 CD44 antigen Mus musculus 139-143 10447778-1 1999 The hyaluronic acid binding glycoprotein CD44 is expressed on a wide variety of cells, and by mediating interactions between cells and extracellular matrices promotes the movement of cells from the circulation into organs. Hyaluronic Acid 4-19 CD44 antigen Mus musculus 41-45 11436704-0 2000 [Differential binding of hyaluronic acid in 2 CD44+ sublines. Hyaluronic Acid 25-40 CD44 antigen Mus musculus 46-50 10757121-1 2000 CD44 is a cell surface glycoprotein involved in cell migration and cell docking in target organs via interactions with various ligands, including hyaluronic acid (HA), which is the principal ligand of this receptor. Hyaluronic Acid 146-161 CD44 antigen Mus musculus 0-4 10757121-1 2000 CD44 is a cell surface glycoprotein involved in cell migration and cell docking in target organs via interactions with various ligands, including hyaluronic acid (HA), which is the principal ligand of this receptor. Hyaluronic Acid 163-165 CD44 antigen Mus musculus 0-4 9721887-0 1998 Site-specific de-N-glycosylation of CD44 can activate hyaluronan binding, and CD44 activation states show distinct threshold densities for hyaluronan binding. Hyaluronic Acid 54-64 CD44 antigen Mus musculus 36-40 9872419-1 1998 Texas red-labeled hyaluronan (TR-HA) is rapidly taken up in a CD44 independent manner into ras-transformed 10T1/2 fibroblasts, where it accumulates in both cell ruffles/lamellae, the perinuclear area, and the nucleus. Hyaluronic Acid 18-28 CD44 antigen Mus musculus 62-66 9634540-1 1998 CD44s (standard isoform), which binds hyaluronan (HA), has been analyzed for its significance during fibrosarcoma progression and metastasis in an athymic nude mouse model using Balb/c 3T3 cells transformed with ras or sis oncogenes. Hyaluronic Acid 38-48 CD44 antigen Mus musculus 0-4 9683538-3 1998 A mAb anti-CD44 (KM 201) dramatically blocked F3II cell adhesion on both plastic and hyaluronic acid coatings, as well as spreading on uncoated plastic surfaces (P < 0.01). Hyaluronic Acid 85-100 CD44 antigen Mus musculus 11-15 9663602-3 1998 Disruption of CD44-hyaluronan interaction by soluble recombinant CD44 has been shown to inhibit tumor formation by lymphoma and melanoma cells transfected with CD44. Hyaluronic Acid 19-29 CD44 antigen Mus musculus 14-18 9663602-3 1998 Disruption of CD44-hyaluronan interaction by soluble recombinant CD44 has been shown to inhibit tumor formation by lymphoma and melanoma cells transfected with CD44. Hyaluronic Acid 19-29 CD44 antigen Mus musculus 65-69 9663602-3 1998 Disruption of CD44-hyaluronan interaction by soluble recombinant CD44 has been shown to inhibit tumor formation by lymphoma and melanoma cells transfected with CD44. Hyaluronic Acid 19-29 CD44 antigen Mus musculus 65-69 9645355-0 1998 Chimeric CD4/CD44 molecules associate with CD44 via the transmembrane region and reduce hyaluronan binding in T cell lines. Hyaluronic Acid 88-98 CD44 antigen Mus musculus 13-17 9637488-7 1998 We also show that hyaluronic acid is the principal ligand on tumor cells for CD44-mediated cytotoxicity of IL-2-activated NK cells. Hyaluronic Acid 18-33 CD44 antigen Mus musculus 77-81 9645355-0 1998 Chimeric CD4/CD44 molecules associate with CD44 via the transmembrane region and reduce hyaluronan binding in T cell lines. Hyaluronic Acid 88-98 CD44 antigen Mus musculus 43-47 9645355-4 1998 This resulted in the reduced ability of endogenous CD44 to constitutively bind hyaluronan. Hyaluronic Acid 79-89 CD44 antigen Mus musculus 51-55 9645355-7 1998 In addition, the association of chimeric CD4/CD44 molecules with endogenous CD44 correlated with reduced hyaluronan binding. Hyaluronic Acid 105-115 CD44 antigen Mus musculus 45-49 9645355-7 1998 In addition, the association of chimeric CD4/CD44 molecules with endogenous CD44 correlated with reduced hyaluronan binding. Hyaluronic Acid 105-115 CD44 antigen Mus musculus 76-80 9645355-8 1998 Thus, the transmembrane region of CD44 is required for the association with CD44 molecules in the cell membrane and we propose that the self-association of CD44 molecules occurs on the T cell surface to promote hyaluronan binding. Hyaluronic Acid 211-221 CD44 antigen Mus musculus 34-38 9645355-8 1998 Thus, the transmembrane region of CD44 is required for the association with CD44 molecules in the cell membrane and we propose that the self-association of CD44 molecules occurs on the T cell surface to promote hyaluronan binding. Hyaluronic Acid 211-221 CD44 antigen Mus musculus 76-80 9645355-8 1998 Thus, the transmembrane region of CD44 is required for the association with CD44 molecules in the cell membrane and we propose that the self-association of CD44 molecules occurs on the T cell surface to promote hyaluronan binding. Hyaluronic Acid 211-221 CD44 antigen Mus musculus 76-80 9645355-9 1998 Cellular events altering the interactions of the transmembrane region of CD44 thus have the potential to regulate the hyaluronan binding ability of CD44. Hyaluronic Acid 118-128 CD44 antigen Mus musculus 73-77 9645355-9 1998 Cellular events altering the interactions of the transmembrane region of CD44 thus have the potential to regulate the hyaluronan binding ability of CD44. Hyaluronic Acid 118-128 CD44 antigen Mus musculus 148-152 9509434-0 1998 Characterization of CD44-mediated hyaluronan binding by renal tubular epithelial cells. Hyaluronic Acid 34-44 CD44 antigen Mus musculus 20-24 9506538-4 1998 Prior characterization of the CD44s and CD44v10 Rg had shown that both Rgs bound to components of the extracellular matrix, CD44s in particular to hyaluronic acid. Hyaluronic Acid 147-162 CD44 antigen Mus musculus 30-34 9506538-4 1998 Prior characterization of the CD44s and CD44v10 Rg had shown that both Rgs bound to components of the extracellular matrix, CD44s in particular to hyaluronic acid. Hyaluronic Acid 147-162 CD44 antigen Mus musculus 40-44 9490645-1 1998 CD44 is a widely expressed cell adhesion molecule that binds the extracellular matrix component, hyaluronan, in a tightly regulated manner. Hyaluronic Acid 97-107 CD44 antigen Mus musculus 0-4 9490645-2 1998 Previous studies have shown that the CD44-hyaluronan interaction is affected by changes in the glycosylation state of CD44. Hyaluronic Acid 42-52 CD44 antigen Mus musculus 37-41 9490645-2 1998 Previous studies have shown that the CD44-hyaluronan interaction is affected by changes in the glycosylation state of CD44. Hyaluronic Acid 42-52 CD44 antigen Mus musculus 118-122 9490645-4 1998 In parental L cells and gro2C cells, CD44 was induced to bind hyaluronan after addition of the activating, anti-CD44 monoclonal antibody, IRAWB 14. Hyaluronic Acid 62-72 CD44 antigen Mus musculus 37-41 9490645-4 1998 In parental L cells and gro2C cells, CD44 was induced to bind hyaluronan after addition of the activating, anti-CD44 monoclonal antibody, IRAWB 14. Hyaluronic Acid 62-72 CD44 antigen Mus musculus 112-116 9490645-8 1998 This indicates that sulfation and, in particular, the addition of chondroitin sulfate are required for inducible hyaluronan binding by CD44 in L cells. Hyaluronic Acid 113-123 CD44 antigen Mus musculus 135-139 9490645-10 1998 Thus, in addition to glycosylation, chondroitin sulfate biosynthesis is an important post-translational modification that can affect the hyaluronan binding ability of CD44. Hyaluronic Acid 137-147 CD44 antigen Mus musculus 167-171 9509434-1 1998 BACKGROUND: CD44 is the main receptor for the extracellular polysaccharide hyaluronan (HA). Hyaluronic Acid 75-85 CD44 antigen Mus musculus 12-16 9509434-1 1998 BACKGROUND: CD44 is the main receptor for the extracellular polysaccharide hyaluronan (HA). Hyaluronic Acid 87-89 CD44 antigen Mus musculus 12-16 9139885-0 1997 Hyaluronan-independent lodgment of CD44+ lymphoma cells in lymphoid organs. Hyaluronic Acid 0-10 CD44 antigen Mus musculus 35-39 9929743-1 1998 The ability of the CD44 adhesion molecule to interact with its ligand hyaluronic acid (HA) is tightly regulated. Hyaluronic Acid 70-85 CD44 antigen Mus musculus 19-23 9929743-1 1998 The ability of the CD44 adhesion molecule to interact with its ligand hyaluronic acid (HA) is tightly regulated. Hyaluronic Acid 87-89 CD44 antigen Mus musculus 19-23 9396767-2 1997 Local release of soluble CD44 by the transfectants inhibited the ability of endogenous cell surface CD44 to bind and internalize hyaluronan and to mediate TA3 cell invasion of hyaluronan-producing cell monolayers. Hyaluronic Acid 129-139 CD44 antigen Mus musculus 25-29 9396767-2 1997 Local release of soluble CD44 by the transfectants inhibited the ability of endogenous cell surface CD44 to bind and internalize hyaluronan and to mediate TA3 cell invasion of hyaluronan-producing cell monolayers. Hyaluronic Acid 129-139 CD44 antigen Mus musculus 100-104 9396767-2 1997 Local release of soluble CD44 by the transfectants inhibited the ability of endogenous cell surface CD44 to bind and internalize hyaluronan and to mediate TA3 cell invasion of hyaluronan-producing cell monolayers. Hyaluronic Acid 176-186 CD44 antigen Mus musculus 25-29 9396767-2 1997 Local release of soluble CD44 by the transfectants inhibited the ability of endogenous cell surface CD44 to bind and internalize hyaluronan and to mediate TA3 cell invasion of hyaluronan-producing cell monolayers. Hyaluronic Acid 176-186 CD44 antigen Mus musculus 100-104 9108410-0 1997 Hyaluronate-CD44 interactions can induce murine B-cell activation. Hyaluronic Acid 0-11 CD44 antigen Mus musculus 12-16 9108410-1 1997 CD44 is a widely distributed cell surface glycoprotein whose principal ligand has been identified as hyaluronic acid (HA), a major component of the extracellular matrix (ECM). Hyaluronic Acid 101-116 CD44 antigen Mus musculus 0-4 9108410-1 1997 CD44 is a widely distributed cell surface glycoprotein whose principal ligand has been identified as hyaluronic acid (HA), a major component of the extracellular matrix (ECM). Hyaluronic Acid 118-120 CD44 antigen Mus musculus 0-4 8750189-0 1995 Molecular mechanisms regulating the hyaluronan binding activity of the adhesion protein CD44. Hyaluronic Acid 36-46 CD44 antigen Mus musculus 88-92 9316589-1 1997 CD44 glycoprotein is the main extracellular receptor for hyaluronic acid. Hyaluronic Acid 57-72 CD44 antigen Mus musculus 0-4 8989516-2 1997 An important ligand for the widespread CD44 isoform, CD44s (standard form of CD44), is hyaluronan but ligands for the numerous variant isoforms are not as well characterized. Hyaluronic Acid 87-97 CD44 antigen Mus musculus 39-43 8989516-2 1997 An important ligand for the widespread CD44 isoform, CD44s (standard form of CD44), is hyaluronan but ligands for the numerous variant isoforms are not as well characterized. Hyaluronic Acid 87-97 CD44 antigen Mus musculus 53-57 8989516-2 1997 An important ligand for the widespread CD44 isoform, CD44s (standard form of CD44), is hyaluronan but ligands for the numerous variant isoforms are not as well characterized. Hyaluronic Acid 87-97 CD44 antigen Mus musculus 53-57 9045958-6 1996 These results suggested that the 2MD3 cell binding to mesothelial cells is regulated by the CD44-hyaluronic acid dependent system. Hyaluronic Acid 97-112 CD44 antigen Mus musculus 92-96 8908201-9 1996 Platelet-derived growth factor (PDGF), when supplementing 0.5% serum, mimicked the effects of serum on the levels and hyaluronan-binding capacity of CD44 in 3T3 cells and the CD44-upregulating activity of serum was neutralized by incubation with anti-PDGF antibodies. Hyaluronic Acid 118-128 CD44 antigen Mus musculus 149-153 8807584-1 1996 The cell surface glycoprotein CD44 is expressed by cells of hematopoietic origin and constitutes a receptor for hyaluronic acid and matrix proteins. Hyaluronic Acid 112-127 CD44 antigen Mus musculus 30-34 8674281-0 1996 Epidermal growth factor modulates cell attachment to hyaluronic acid by the cell surface glycoprotein CD44. Hyaluronic Acid 53-68 CD44 antigen Mus musculus 102-106 8674281-10 1996 Thus, EGF stimulates cell binding to hyaluronate in vitro by regulating CD44 expression. Hyaluronic Acid 37-48 CD44 antigen Mus musculus 72-76 8698379-4 1996 Hyaluronic acid (HA), a ligand of Pgp-1, did not affect proliferation and deletion induced by SEB, whereas it mimicked the effects of the cross-linked antibody in anti-CD3-driven proliferation. Hyaluronic Acid 0-15 CD44 antigen Mus musculus 34-39 8698379-4 1996 Hyaluronic acid (HA), a ligand of Pgp-1, did not affect proliferation and deletion induced by SEB, whereas it mimicked the effects of the cross-linked antibody in anti-CD3-driven proliferation. Hyaluronic Acid 17-19 CD44 antigen Mus musculus 34-39 7497529-5 1995 They were recently found to express a higher level of CD44 antigen, which is a ligand for hyaluronic acid, than that of another T cell subset (i.e., thymus-derived T cells or bright TCR cells). Hyaluronic Acid 90-105 CD44 antigen Mus musculus 54-58 8649770-0 1996 Overexpression of CD44 in pl85(neu)-transfected NIH3T3 cells promotes an up-regulation of hyaluronic acid-mediated membrane-cytoskeleton interaction and cell adhesion. Hyaluronic Acid 90-105 CD44 antigen Mus musculus 18-22 8649770-1 1996 CD44 is a transmembrane glycoprotein known to bind hyaluronic acid (HA) in its extracellular domain and to contain at least one ankyrin-binding site in its cytoplasmic domain. Hyaluronic Acid 51-66 CD44 antigen Mus musculus 0-4 8649770-1 1996 CD44 is a transmembrane glycoprotein known to bind hyaluronic acid (HA) in its extracellular domain and to contain at least one ankyrin-binding site in its cytoplasmic domain. Hyaluronic Acid 68-70 CD44 antigen Mus musculus 0-4 8669459-0 1996 Increased hyaluronan at sites of attachment to mesentery by CD44-positive mouse ovarian and breast tumor cells. Hyaluronic Acid 10-20 CD44 antigen Mus musculus 60-64 8669459-7 1996 We propose that hyaluronan-rich matrix is involved in tumor cell attachment to the mesentery possibly via interaction with tumor cell surface CD44. Hyaluronic Acid 16-26 CD44 antigen Mus musculus 142-146 8750189-1 1995 In the present study, we describe the isolation and characterization of a cDNA clone designated B6F1.3, that appears to "activate" the hyaluronan-binding capacity of CD44 upon transfection into the murine fibroblastoid cell line MOP8. Hyaluronic Acid 135-145 CD44 antigen Mus musculus 166-170 7543138-1 1995 CD44 is a major cell surface receptor for the extracellular matrix glycosaminoglycan hyaluronan (HA). Hyaluronic Acid 85-95 CD44 antigen Mus musculus 0-4 8846023-7 1995 Hyaluronan, the major ligand for CD44, is also associated with these CD44-positive fibroblast-like cells. Hyaluronic Acid 0-10 CD44 antigen Mus musculus 33-37 8846023-7 1995 Hyaluronan, the major ligand for CD44, is also associated with these CD44-positive fibroblast-like cells. Hyaluronic Acid 0-10 CD44 antigen Mus musculus 69-73 7543138-1 1995 CD44 is a major cell surface receptor for the extracellular matrix glycosaminoglycan hyaluronan (HA). Hyaluronic Acid 97-99 CD44 antigen Mus musculus 0-4 7529138-7 1995 The presence of hyaluronan did enhance the interaction of the HA-H cells with cultured endothelial cells that expressed CD44. Hyaluronic Acid 16-26 CD44 antigen Mus musculus 120-124 7537306-8 1995 PMA activation also enabled in vitro binding of the lymphoma to hyaluronic acid (HA), a known ligand of CD44. Hyaluronic Acid 64-79 CD44 antigen Mus musculus 104-108 7537306-8 1995 PMA activation also enabled in vitro binding of the lymphoma to hyaluronic acid (HA), a known ligand of CD44. Hyaluronic Acid 81-83 CD44 antigen Mus musculus 104-108 7535820-0 1995 Hyaluronic acid enhances cell proliferation during eosinopoiesis through the CD44 surface antigen. Hyaluronic Acid 0-15 CD44 antigen Mus musculus 77-81 7535820-1 1995 We examined the effect of hyaluronic acid in promoting proliferation of undifferentiated progenitor cells through the CD44 receptor during eosinopoiesis in vitro. Hyaluronic Acid 26-41 CD44 antigen Mus musculus 118-122 7535820-8 1995 Augmented proliferation caused by hyaluronic acid was attenuated completely by the anti-CD44 mAbs, 212.3 and IM7.8.1. Hyaluronic Acid 34-49 CD44 antigen Mus musculus 88-92 7585123-1 1995 A ubiquitous cell adhesion receptor, CD44, preferentially binds hyaluronan, a polysaccharide macromolecule that is present in most extracellular matrices. Hyaluronic Acid 64-74 CD44 antigen Mus musculus 37-41 7516415-0 1994 Hyaluronan binding function of CD44 is transiently activated on T cells during an in vivo immune response. Hyaluronic Acid 0-10 CD44 antigen Mus musculus 31-35 7534265-8 1995 Hyaluronic acid, which is known to adhere to a CD44 ligand, bound to intermediate TCR cells, but not to bright TCR cells. Hyaluronic Acid 0-15 CD44 antigen Mus musculus 47-51 8867646-11 1995 The effects noted when diclofenac is formulated in hyaluronan, and applied topically, could be related to trans-dermal delivery and deposition properties of hyaluronan, and to the binding properties of hyaluronan to areas of pathology with high expression of hyaluronan receptors such as RHAMM, ICAM-1, and CD44. Hyaluronic Acid 51-61 CD44 antigen Mus musculus 307-311 7504026-0 1993 Hyaluronan is inversely correlated with the expression of CD44 in the dermal condensation of the embryonic hair follicle. Hyaluronic Acid 0-10 CD44 antigen Mus musculus 58-62 7514628-5 1994 The disruption of hyaluronic acid (HA), one of the ligands of CD44, by hyaluronidase or the competition for the binding of CD44 by soluble HA added with IL-2 on day 0 inhibited both proliferation and development of cytotoxicity to a greater degree than did anti-CD44. Hyaluronic Acid 18-33 CD44 antigen Mus musculus 62-66 7514628-5 1994 The disruption of hyaluronic acid (HA), one of the ligands of CD44, by hyaluronidase or the competition for the binding of CD44 by soluble HA added with IL-2 on day 0 inhibited both proliferation and development of cytotoxicity to a greater degree than did anti-CD44. Hyaluronic Acid 35-37 CD44 antigen Mus musculus 62-66 7505012-0 1993 Hyaluronic acid-induced lymphocyte signal transduction and HA receptor (GP85/CD44)-cytoskeleton interaction. Hyaluronic Acid 0-15 CD44 antigen Mus musculus 77-81 7505012-8 1993 These findings strongly suggest that ankyrin plays an important role in linking the HA receptor, GP85(CD44), to the membrane-associated actomyosin contractile system during hyaluronic acid-mediated lymphocyte activation. Hyaluronic Acid 173-188 CD44 antigen Mus musculus 102-106 7504026-1 1993 Previously, we have shown that CD44 (the hyaluronan receptor) was involved in the degradation of hyaluronan. Hyaluronic Acid 41-51 CD44 antigen Mus musculus 31-35 7504026-11 1993 The results of this study are consistent with the hypothesis that the expression of CD44 by the inductive mesenchymal cells allows them to degrade hyaluronan in a localized region, leading to formation and maintenance of the dermal condensation. Hyaluronic Acid 147-157 CD44 antigen Mus musculus 84-88 7507029-7 1993 Between 9.5 and 12.5 days of embryonic development, the predominant form of CD44 protein corresponds to the hyaluronan-binding CD44H form. Hyaluronic Acid 108-118 CD44 antigen Mus musculus 76-80 7694807-7 1993 One of the ligands for CD44 is hyaluronic acid. Hyaluronic Acid 31-46 CD44 antigen Mus musculus 23-27 7507029-7 1993 Between 9.5 and 12.5 days of embryonic development, the predominant form of CD44 protein corresponds to the hyaluronan-binding CD44H form. Hyaluronic Acid 108-118 CD44 antigen Mus musculus 127-131 7507029-12 1993 Of novel interest, however, is the high expression of CD44 in regions that do not correlate with sites of known hyaluronan-mediated developmental events. Hyaluronic Acid 112-122 CD44 antigen Mus musculus 54-58 8514850-0 1993 Hyaluronate activation of CD44 induces insulin-like growth factor-1 expression by a tumor necrosis factor-alpha-dependent mechanism in murine macrophages. Hyaluronic Acid 0-11 CD44 antigen Mus musculus 26-30 8514850-4 1993 Monoclonal antibodies to the hyaluronic acid receptor CD44 blocked the effects of hyaluronic acid on IL-1 beta, TNF alpha, and IGF-1 expression. Hyaluronic Acid 29-44 CD44 antigen Mus musculus 54-58 8514850-10 1993 These results indicate that hyaluronate activation of CD44 induces cytokine expression and macrophage-derived IGF-1 production is dependent on TNF alpha expression. Hyaluronic Acid 28-39 CD44 antigen Mus musculus 54-58 8095198-7 1993 Despite higher ICAM-1 levels, cell aggregation assays revealed that LFA-1-ICAM-1 adhesive interactions were not involved in the homotypic adhesion of B9/BM1 cells but rather that binding of CD44 to endogenously-synthesized hyaluronan was responsible. Hyaluronic Acid 223-233 CD44 antigen Mus musculus 190-194 2044660-1 1991 The cell surface molecule CD44, thought to be a cell surface receptor for hyaluronic acid, is expressed by thymocytes and peripheral T cells. Hyaluronic Acid 74-89 CD44 antigen Mus musculus 26-30 1382996-1 1992 The hyaluronic acid (HA)-binding function of CD44 expressed on the cell surface of normal hematopoietic cells has been studied by assaying binding of fluoresceinated hyaluronic acid (F1-HA) and adhesion to immobilized HA. Hyaluronic Acid 4-19 CD44 antigen Mus musculus 45-49 1382996-1 1992 The hyaluronic acid (HA)-binding function of CD44 expressed on the cell surface of normal hematopoietic cells has been studied by assaying binding of fluoresceinated hyaluronic acid (F1-HA) and adhesion to immobilized HA. Hyaluronic Acid 21-23 CD44 antigen Mus musculus 45-49 1370836-0 1992 The hyaluronan receptor (CD44) participates in the uptake and degradation of hyaluronan. Hyaluronic Acid 4-14 CD44 antigen Mus musculus 25-29 8432391-0 1993 CD44 positive macrophages take up hyaluronan during lung development. Hyaluronic Acid 34-44 CD44 antigen Mus musculus 0-4 8432391-8 1993 As development progressed, the macrophages expressing CD44 increased in number, and this increase was temporarily correlated with the decrease in hyaluronan content. Hyaluronic Acid 146-156 CD44 antigen Mus musculus 54-58 34380333-12 2021 Mechanistically, blocking selectively the hyaluronan binding site of CD44 reduced flow-mediated dilation, thereby suggesting hyaluronan signaling through CD44 as the underlying signaling pathway. Hyaluronic Acid 42-52 CD44 antigen Mus musculus 69-73 2180732-0 1990 Binding of hyaluronic acid to lymphoid cell lines is inhibited by monoclonal antibodies against Pgp-1. Hyaluronic Acid 11-26 CD44 antigen Mus musculus 96-101 2180732-1 1990 Recent biochemical and sequence data suggest a possible relationship between Pgp-1 (identical to CD44/Hermes 1/p85) and a hyaluronic acid-binding function. Hyaluronic Acid 122-137 CD44 antigen Mus musculus 77-82 2180732-1 1990 Recent biochemical and sequence data suggest a possible relationship between Pgp-1 (identical to CD44/Hermes 1/p85) and a hyaluronic acid-binding function. Hyaluronic Acid 122-137 CD44 antigen Mus musculus 97-101 2180732-3 1990 Certain Pgp-1-positive T and B cell lines show hyaluronic acid binding that is highly specific and is not competed for by other glycosaminoglycans. Hyaluronic Acid 47-62 CD44 antigen Mus musculus 8-13 2180732-4 1990 Monoclonal antibodies against Pgp-1, but not antibodies against other major cell surface glycoproteins, inhibited hyaluronic acid-induced cell aggregation and cell adhesion to hyaluronic acid-coated dishes. Hyaluronic Acid 114-129 CD44 antigen Mus musculus 30-35 2180732-4 1990 Monoclonal antibodies against Pgp-1, but not antibodies against other major cell surface glycoproteins, inhibited hyaluronic acid-induced cell aggregation and cell adhesion to hyaluronic acid-coated dishes. Hyaluronic Acid 176-191 CD44 antigen Mus musculus 30-35 2180732-5 1990 Additionally, some anti-Pgp-1 antibodies inhibited binding of fluorescein-hyaluronic acid to hyaluronic acid-binding lines. Hyaluronic Acid 74-89 CD44 antigen Mus musculus 24-29 2180732-7 1990 Two Pgp-1-positive thymomas that did not bind hyaluronic acid were induced by phorbol ester to bind hyaluronic acid with the same specificity as other hyaluronic acid-binding lines. Hyaluronic Acid 100-115 CD44 antigen Mus musculus 4-9 2180732-7 1990 Two Pgp-1-positive thymomas that did not bind hyaluronic acid were induced by phorbol ester to bind hyaluronic acid with the same specificity as other hyaluronic acid-binding lines. Hyaluronic Acid 100-115 CD44 antigen Mus musculus 4-9 2180732-9 1990 We discuss several models that might account for these observations: (1) the hyaluronic acid receptor is Pgp-1, but it normally exists in an inactive state; (2) hyaluronic acid receptors are a subset of a family of molecules recognized by anti-Pgp-1 antibodies; (3) the hyaluronic acid receptor is not Pgp-1, but is closely associated with Pgp-1 on the surface of cells which express hyaluronic acid-binding activity. Hyaluronic Acid 77-92 CD44 antigen Mus musculus 105-110 2180732-9 1990 We discuss several models that might account for these observations: (1) the hyaluronic acid receptor is Pgp-1, but it normally exists in an inactive state; (2) hyaluronic acid receptors are a subset of a family of molecules recognized by anti-Pgp-1 antibodies; (3) the hyaluronic acid receptor is not Pgp-1, but is closely associated with Pgp-1 on the surface of cells which express hyaluronic acid-binding activity. Hyaluronic Acid 77-92 CD44 antigen Mus musculus 244-249 2180732-9 1990 We discuss several models that might account for these observations: (1) the hyaluronic acid receptor is Pgp-1, but it normally exists in an inactive state; (2) hyaluronic acid receptors are a subset of a family of molecules recognized by anti-Pgp-1 antibodies; (3) the hyaluronic acid receptor is not Pgp-1, but is closely associated with Pgp-1 on the surface of cells which express hyaluronic acid-binding activity. Hyaluronic Acid 77-92 CD44 antigen Mus musculus 244-249 2180732-9 1990 We discuss several models that might account for these observations: (1) the hyaluronic acid receptor is Pgp-1, but it normally exists in an inactive state; (2) hyaluronic acid receptors are a subset of a family of molecules recognized by anti-Pgp-1 antibodies; (3) the hyaluronic acid receptor is not Pgp-1, but is closely associated with Pgp-1 on the surface of cells which express hyaluronic acid-binding activity. Hyaluronic Acid 77-92 CD44 antigen Mus musculus 244-249 34864404-0 2022 Redox sensitive nano-capsules self-assembled from hyaluronic acid-hydroxychloroquine conjugates for CD44-targeted delivery of hydroxychloroquine to combat breast cancer metastasis in vitro and in vivo. Hyaluronic Acid 50-65 CD44 antigen Mus musculus 100-104 34380333-12 2021 Mechanistically, blocking selectively the hyaluronan binding site of CD44 reduced flow-mediated dilation, thereby suggesting hyaluronan signaling through CD44 as the underlying signaling pathway. Hyaluronic Acid 42-52 CD44 antigen Mus musculus 154-158 34217824-3 2021 To address the side- effects in non-target organs and systemic toxicity of FK506, pH-responsive Eudragit S100 (ES100) and hyaluronic acid (HA) with high affinity to CD44 receptor were adsorbed onto the surface of chitosan (CS) nanoparticles loaded with FK506/HP-beta-CD through electrostatic interactions to obtain FK506@ES100/HA/CS/HP-beta-CD nanoparticles (FK506@EHCh NPs). Hyaluronic Acid 122-137 CD44 antigen Mus musculus 165-169 34310958-3 2021 Sequential (double-stage) targeting was achieved at the cellular-level employing the selective CD44- receptor binding hyaluronic acid (HA), followed by subcellular mitochondrial drug-delivery using a synthesized triphenylphosphonium-conjugated doxorubicin (DOX-TPP+). Hyaluronic Acid 118-133 CD44 antigen Mus musculus 95-99 34310958-3 2021 Sequential (double-stage) targeting was achieved at the cellular-level employing the selective CD44- receptor binding hyaluronic acid (HA), followed by subcellular mitochondrial drug-delivery using a synthesized triphenylphosphonium-conjugated doxorubicin (DOX-TPP+). Hyaluronic Acid 135-137 CD44 antigen Mus musculus 95-99 35079755-6 2022 Hyaluronic acid provided stability and enhanced the intracellular uptake of insoluble Prussian blue via the CD44 receptor on LPS-activated macrophages. Hyaluronic Acid 0-15 CD44 antigen Mus musculus 108-112 35429379-0 2022 CD44 is critical for the enhancing effect of hyaluronan in allergen-specific sublingual immunotherapy in a murine model of chronic asthma. Hyaluronic Acid 45-55 CD44 antigen Mus musculus 0-4 35152139-0 2022 Interaction between CD44 and highly condensed hyaluronic acid through crosslinking with proteins. Hyaluronic Acid 46-61 CD44 antigen Mus musculus 20-24 34575403-4 2021 To overcome the current limitations and enhance the therapeutic effects, epigallocatechin-3-gallate (EGCG) and low-concentration doxorubicin (DX) were encapsulated in fucoidan and d-alpha-tocopherylpoly (ethylene glycol) succinate-conjugated hyaluronic acid-based NPs for targeting P-selectin-and cluster of differentiation (CD)44-expressing gastric tumors. Hyaluronic Acid 242-257 CD44 antigen Mus musculus 324-330 35214154-3 2022 The obtained hybrid PNPs can be internalized into drug-resistant breast cancer cells by the hyaluronic acid/CD44-mediated endocytosis pathway and escape from the lysosome through the "proton sponge effect". Hyaluronic Acid 92-107 CD44 antigen Mus musculus 108-112 35069598-1 2021 Interactions between CD44 and hyaluronan (HA) are crucial for recruiting leukocytes to inflamed tissues. Hyaluronic Acid 30-40 CD44 antigen Mus musculus 21-25